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Each of us receives multiple vaccinations since our birth, which protect us from 
many infectious pathogens.  These vaccines establish long-term protection through 
generating a memory subset of lymphocytes.  This study explores whether CD23, an Fcε 
receptor, and a high fat diet have any role in regulating the generation of memory B cells.  
The role of CD23 in B cells was examined using CD23 transgenic mice.  My data show 
that both mouse and human memory B cells express lower levels of CD23 than follicular 
B cells.  In response to antigenic stimulation, CD23 co-aggregates with the B cell 
receptor.  However, the percentages of isotype switched B cells as well as other major 
peripheral B cell subsets in the spleen are not altered in unimmunized CD23 transgenic 
mice, where B cells express 1.5 fold of the normal level of CD23, in comparison to those 
of wild type mice.  This implicates that CD23 does not have any significant role in the 
generation of memory B cells. 
The impact of diet on B cells was examined using mice fed with a high fat and/or 
high cholesterol diet.  The mice used possessed either a knockout of the gene NPC1L1, 
an intestinal cholesterol transporter or the wild type gene as an additional level of control.  
In comparison with mice fed a normal Chow diet and NPC1L1 knockout mice, neither a 
high fat diet nor a high fat/high cholesterol diet caused any significant changes in the 
percentages of isotype switched B cells in the spleen.  However, both the high fat diet 
with and without high cholesterol led to increases in the percentages of mature follicular 
B cells and decreases in the percentage of transitional B cells in a NPC1L1 independent 
manner.  Furthermore, the percentage of marginal zone B cells is significantly increased 
in the spleens of mice fed with high fat and high cholesterol diet.  This result suggests a 
possible role of high fat and high cholesterol diet in regulating the peripheral 













B CELL MEMORY, CD23, AND LIPID METABOLISM: A PRELIMINARY STUDY 
by 





Thesis submitted to the Faculty of the Graduate School of the 
University of Maryland, College Park in partial fulfillment 
of the requirements for the degree of 

















Professor Wenxia Song, Chair 
Professor Kenneth Frauwirth 






























	   ii	  
DEDICATION 
 
To the only true super hero I have ever met and the greatest guarding angel a son could 
ever have… Janice D. Montgomery. 
Rest in peace.
	   iii	  
ACKNOWLEDGEMENTS 
 
First and foremost I would like to extend my deepest and most sincere thanks to 
Dr. Wenxia Song for her understanding, honesty, dedication, and guidance throughout 
the completion of my work at the University of Maryland.  Her inspiring life story, which 
illustrates best the sheer power of determination in the face of difficult challenges, served 
as a great motivator to me throughout my time in her lab and even helped me to 
overcome difficulties in my personal life.  To you, Dr. Song, I am indebted--for without 
you none of this would have been even remotely possible! 
A big ‘thank you’ also goes to Dr. Kenneth Frauwirth for being not only a 
veritable encyclopedia on a great variety of topics in science, but also for being able to 
communicate that knowledge in understandable and clear terms.  Dr. Frauwirth, you are 
truly a rare and valuable resource and I wish nothing but the best for you in any future 
endeavors you choose to undertake.  To Dr. David Mosser, I would like to extent thanks 
for offering a more practical view to scientific research (which can sometimes be in short 
supply at academic institutions).  You helped me to always consider the overall practical 
importance of any given research and to not lose sight of the big picture when developing 
my research or even when reading the latest breakthrough journal article.  Dr. Zhengguo 
Xiao, I thank you for your thought provoking questions which constantly forced me to 
think about my project in new and interesting ways.  It is my opinion, that science is only 
truly moved forward when bold and uncommon questions are asked and then answered.  
To me, Dr. Xiao was the embodiment of this principle.  To Dr. Silvia Muro, I would like 
to thank for offering great suggestions for improving my own knowledge and 
development as a scientist.  Many of the things we discussed and that you suggested will 
undoubtedly aid in my development and help me to accomplish much more in my career.  
And to Dr. Liqing Yu, I thank you for giving me an opportunity to collaborate with you 
and your lab on the B cell portion of your cholesterol transporter/obesity project. 
I would also like to thank Dr. Daniel Conrad at the Virginia Commonwealth 
University in Richmond, Virginia for donating both the CD23 transgenic and CD23 
knock out mice to the Song lab for this project.  His generosity and willingness to offer 
information regarding various experimental protocols was invaluable and greatly 
appreciated. 
I would also like to acknowledge the great contributions of Amy Beaven of the 
CBMG Imaging Core Facility as well as Kenneth Class of the MPRI Flow Cytometry and 
Cell Sorting Facility.  Their extensive knowledge, expertise and willingness to 
assist/troubleshoot (many times well beyond their scheduled hours) were more than 
appreciated.  And to my friends Dr. Katharina Richard, Dr. Karen Swanson, Dr. Vonetta 
Edwards, Margaret ‘Katie’ Fallen, Heather Miller, Liang Chun ‘Mark’ Wang, Chaohong 
Liu, Senthil Velan, Dr. Hongming Miao, Clinton Miller, Yuan Li, and Hiromi Yoshida 
for their constant inspiration and support. 
And last, but not least I would like to extend thanks to Dr. Michelle Brooks, Sarah 
Biancardi, LaJeune Stover and the entire administrative MOCB/CBMG staff for helping 
to make this possible.  Thank you all! 
	   iv	  
TABLE OF CONTENTS 
DEDICATION................................................................................................................................................ ii	  
TABLE	  OF	  CONTENTS ............................................................................................................................ iv	  
LIST	  OF	  FIGURES ........................................................................................................................................v	  
LIST	  OF	  TABLES.......................................................................................................................................vii	  
ABBREVIATIONS ....................................................................................................................................viii	  
INTRODUCTION ......................................................................................................................................... 1	  
The	  Immune	  System............................................................................................................................ 2	  
The	  B	  Lymphocyte................................................................................................................................ 6	  
B	  Lymphocyte	  Activation .................................................................................................................. 7	  
Memory	  B	  Cells....................................................................................................................................10	  
The	  CD23/FcεRII	  Molecule.............................................................................................................12	  
Lipid	  Metabolism	  and	  Immunity..................................................................................................14	  
METHODS ...................................................................................................................................................18	  
Isolation	  of	  B	  cells...............................................................................................................................18	  
Mouse	  Models ......................................................................................................................................18	  
In	  vitro	  Activation	  of	  B	  cells ...........................................................................................................19	  
Immunofluorescence	  Microscopy	  Analysis.............................................................................19	  
Flow	  Cytometry	  Analysis ................................................................................................................20	  
Mouse	  Diet	  Treatment......................................................................................................................22	  
RESULTS......................................................................................................................................................23	  
Do	  memory	  B	  cells	  alter	  their	  levels	  of	  CD23	  expression? ...............................................23	  
How	  much	  do	  the	  B	  cells	  in	  CD23	  transgenic	  mice	  over-­‐express	  CD23? ...................25	  
Does	  CD23	  over-­‐expression	  in	  CD23	  transgenic	  mice	  affect	  B	  cell	  subsets	  in	  the	  
spleen?.....................................................................................................................................................27	  
Does	  CD23	  co-­‐cluster	  with	  B	  cell	  receptor	  in	  response	  to	  antigen	  stimulation?....30	  
Does	  high	  fat	  diet	  affect	  the	  development	  of	  peripheral	  B	  cells?...................................31	  
SUMMARY	  OF	  PRELIMINARY	  DATA ...............................................................................................43	  
FUTURE	  DIRECTIONS............................................................................................................................49	  
Future	  Project	  #1:	  Identify	  the	  steps	  in	  memory	  B	  cell	  responses	  where	  CD23	  
plays	  a	  role.............................................................................................................................................49	  





	   v	  
LIST OF FIGURES 
FIGURE	  1:	  SIMPLIFIED	  MODEL	  OF	  B	  CELL	  ACTIVATION	  [17].......................................................................................................6	  
FIGURE	  2:	  SCHEMATIC	  OF	  THE	  B	  CELL	  RECEPTOR	  COMPLEX	  [21]. ............................................................................................9	  
FIGURE	  3:	  DIAGRAM	  DISPLAYING	  SERUM	  ANTIBODY	  TITER	  AFTER	  PRIMARY	  AND	  SECONDARY	  IMMUNIZATION	  WITH	  
GENERIC	  'ANTIGEN	  A'	  [31]................................................................................................................................................11	  
FIGURE	  4:	  CD23	  EXPRESSION	  IN	  HUMAN	  MEMORY	  B	  CELLS.	  (A-­‐C)	  REPRESENTATIVE	  HISTOGRAMS	  OF	  FIVE	  
INDEPENDENT	  EXPERIMENTS	  DISPLAYING	  MEAN	  FLUORESCENCE	  INTENSITY	  OF	  CD23	  EXPRESSION	  ON	  HUMAN24	  
FIGURE	  5:	  CD23	  EXPRESSION	  IN	  MOUSE	  B	  CELLS.	  REPRESENTATIVE	  HISTOGRAMS	  OF	  TWO	  INDEPENDENT	  
EXPERIMENTS,	  DISPLAYING	  MEAN	  FLUORESCENCE	  INTENSITY	  OF	  CD23	  EXPRESSION	  ON	  (A)	  MOUSE	  NAÏVE	  B	  
CELLS	  (LEFT	  ROW	  OF	  HISTOGRAMS)	  AND	  (B)	  MOUSE	  ISOTYPE	  SWITCHED	  B	  CELLS	  (RIGHT	  ROW	  OF	  HISTOGRAMS).	  	  
SPLENIC	  MOUSE	  B	  CELLS	  WERE	  STAINED	  WITH	  ANTI-­‐B220	  (B	  CELL	  MARKER),	  ANTI-­‐IGM,	  ANTI-­‐IGD,	  ANTI-­‐
CD138	  (PLASMA	  CELL	  MARKER),	  AND	  ANTI-­‐CD23	  BEFORE	  ANALYSIS	  WITH	  FLOW	  CYTOMETRY.	  B220+	  IGM+	  
AND/OR	  IGD+	  CELLS	  WERE	  GATED	  AS	  NAÏVE	  B	  CELLS	  AND	  B220+	  IGM-­‐	  IGD-­‐	  CELLS	  WERE	  GATED	  AS	  ISOTYPE	  
SWITCHED	  B	  CELLS.	  (C)	  SHOWN	  ARE	  THE	  AVERAGE	  MFI	  VALUES	  (+SD)	  FROM	  TWO	  INDEPENDENT	  
EXPERIMENTS	  USING	  THREE	  MICE	  PER	  EXPERIMENT	  (P=0.050). ...............................................................................25	  
FIGURE	  6:	  COMPARISON	  OF	  CD23	  EXPRESSION	  IN	  TOTAL	  (A)	  LIVE	  CELLS	  AND	  (B)	  B	  CELLS	  ONLY.	  MOUSE	  
SPLENOCYTES	  WERE	  STAINED	  WITH	  ANTI-­‐B220	  (B	  CELL	  MARKER),	  ANTI-­‐CD138	  (PLASMA	  CELL	  MARKER),	  AND	  
ANTI-­‐CD23	  BEFORE	  ANALYSIS	  USING	  FLOW	  CYTOMETRY.	  B220+	  CD138-­‐	  CELLS	  WERE	  GATED	  AS	  B	  CELLS	  AND	  
LIVE	  CELLS	  ARE	  GATED	  BASED	  ON	  THE	  FORWARD	  SCATTER	  (FSC)	  AND	  SIDE	  SCATTER	  (SSC).	  SHOWN	  ARE	  THE	  
AVERAGE	  MFI	  VALUES	  (+SD)	  FROM	  TWO	  INDEPENDENT	  EXPERIMENTS	  USING	  THREE	  MICE	  PER	  EXPRESSION	  
STRAIN	  (WT,	  TG,	  AND	  KO).	  6A	  P-­‐VALUES	  (WT	  V	  TG/WT	  V	  KO/TG	  V	  KO):	  0.282/0.013/0.077.	  6B	  P-­‐
VALUES	  (WT	  V	  TG/WT	  V	  KO/	  TG	  V	  KO):	  0.250/0.013/0.062.	  WT:	  WILD	  TYPE	  MICE;	  TG:	  CD23	  
TRANSGENIC	  MICE;	  KO:	  CD23	  KNOCK	  OUT	  MICE. ..........................................................................................................27	  
FIGURE	  7:	  EFFECT	  OF	  CD23	  OVER-­‐EXPRESSION	  ON	  B	  CELL	  SUBSETS	  IN	  THE	  SPLEEN.	  	  MOUSE	  B	  CELLS	  WERE	  STAINED	  
WITH	  ANTI-­‐B220	  (B	  CELL	  MARKER),	  ANTI-­‐CD138	  (PLASMA	  CELL	  MARKER),	  ANTI-­‐IGM,	  ANTI-­‐IGD,	  ANTI-­‐
CD24,	  ANTI-­‐CD21,	  AND	  ANTI-­‐CD23	  BEFORE	  BEING	  ANALYZED	  BY	  FLOW	  CYTOMETRY.	  	  (A)	  THE	  FOLLICULAR	  B	  
CELL	  SUBSET	  (FO)	  WAS	  GATED	  AS	  B220+	  CD138-­‐IGMLO	  IGD+	  CD23+	  CD21INT	  (GREEN	  BARS),	  (B)	  THE	  
MARGINAL	  ZONE	  B	  CELL	  SUBSET	  (MZ)	  WAS	  GATED	  AS	  B220+	  CD138-­‐	  IGMHI	  IGD-­‐	  CD23LO	  CD21HI	  
(MAROON	  BARS),	  (C)	  THE	  TRANSITIONAL	  1	  B	  CELL	  SUBSET	  WAS	  GATED	  AS	  B220+	  CD138-­‐	  IGM+	  IGD+	  
CD21LO	  CD23+	  (BLUE	  BARS),	  AND	  (D)	  THE	  TRANSITIONAL	  2	  B	  CELL	  SUBSET	  WAS	  GATED	  AS	  B220+	  CD138-­‐	  
IGM+	  IGD-­‐	  CD21LO	  CD23+	  (GREY	  BARS).	  SHOWN	  ARE	  THE	  AVERAGE	  PERCENTAGES	  (+SD)	  FROM	  TWO	  
INDEPENDENT	  EXPERIMENTS	  USING	  THREE	  MICE	  PER	  EXPRESSION	  STRAIN	  (WT,	  TG,	  AND	  KO).	  7A	  P-­‐VALUES	  
(WT	  V	  TG/WT	  V	  KO/TG	  V	  KO):	  0.755/0.179/0.096.	  7B	  P-­‐VALUES	  (WT	  V	  TG/WT	  V	  KO/TG	  V	  KO):	  
0.371/0.090/0.033.	  7C	  P-­‐VALUES	  (WT	  V	  TG/WT	  V	  KO/TG	  V	  KO):	  0.460/0.645/0.011.	  7D	  P-­‐VALUES	  
(WT	  V	  TG/WT	  V	  KO/TG	  V	  KO):	  0.496/0.145/0.791.............................................................................................29	  
FIGURE	  8:	  EFFECT	  OF	  CD23	  OVER-­‐EXPRESSION	  ON	  THE	  ISOTYPE	  SWITCHED	  B	  CELL	  SUBSET	  IN	  THE	  SPLEEN.	  MOUSE	  B	  
CELLS	  WERE	  STAINED	  WITH	  ANTI-­‐B220	  (B	  CELL	  MARKER),	  ANTI-­‐CD138	  (PLASMA	  CELL	  MARKER),	  ANTI-­‐IGM,	  
ANTI-­‐IGD,	  ANTI-­‐CD24,	  ANTI-­‐CD21,	  AND	  ANTI-­‐CD23	  BEFORE	  BEING	  ANALYZED	  BY	  FLOW	  CYTOMETRY.	  THE	  
ISOTYPE	  SWITCHED	  B	  CELL	  SUBSET	  WAS	  GATED	  AS	  B220+	  CD138-­‐	  IGM-­‐	  IGD-­‐	  CD21+	  CD23LO.	  	  SHOWN	  ARE	  
THE	  AVERAGE	  PERCENTAGES..............................................................................................................................................29	  
FIGURE	  9:	  THE	  SURFACE	  DISTRIBUTION	  OF	  CD23	  IN	  STIMULATED	  AND	  UN-­‐STIMULATED	  HUMAN	  B	  CELLS.	  B	  CELLS	  
WERE	  TREATED	  WITH	  FLUORESCENTLY-­‐LABELED	  ANTI-­‐IGG+M	  F(AB’)2	  ANTIBODIES	  TO	  SIMULATE	  
INTERACTIONS	  WITH	  SOLUBLE	  ANTIGEN	  FOR	  5,	  10,	  15,	  AND	  20	  MINUTES	  IN	  A	  37°C	  INCUBATION	  CHAMBER.	  	  
CELLS	  INCUBATED	  FOR	  0	  MINUTES	  WERE	  USED	  AS	  UN-­‐STIMULATED	  CONTROL	  SAMPLES.	  	  AFTER	  STIMULATION,	  
THE	  CELLS	  WERE	  IMMEDIATELY	  TRANSFERRED	  TO	  4°C	  CONDITIONS	  AND	  STAINED	  WITH	  FLUORESCENTLY-­‐
LABELED	  ANTI-­‐CD19,	  ANTI-­‐CD27,	  AND	  ANTI-­‐CD23	  ANTIBODIES.	  CELLS	  WERE	  FIXED	  WITH	  4%	  
PARAFORMALDEHYDE	  (PFA)	  SOLUTION	  MIXED	  IN	  NON-­‐STERILE	  PHOSPHATE	  BUFFERED	  SALINE	  (PBS).	  B	  CELL	  
RECEPTOR	  IS	  REPRESENTED	  IN	  RED	  AND	  CD23	  IS	  REPRESENTED	  IN	  GREEN.	  SHOWN	  ARE	  REPRESENTATIVE	  
IMAGES	  FROM	  FIVE	  EXPERIMENTS. ....................................................................................................................................31	  
FIGURE	  10:	  EFFECTS	  OF	  HIGH	  FAT	  DIET	  ON	  SPLENIC	  FO	  B	  CELLS	  OF	  WILD	  TYPE	  (A)	  AND	  L1	  KO	  MICE	  (B)	  AFTER	  HIGH	  
FAT	  DIET.	  MICE	  WERE	  FED	  EITHER	  A	  NORMAL	  CHOW	  DIET,	  A	  HIGH	  FAT	  DIET	  WITH	  LOW	  CHOLESTEROL	  (<0.02%	  
	   vi	  
CHOLESTEROL)),	  OR	  A	  HIGH	  FAT	  DIET	  WITH	  HIGH	  CHOLESTEROL	  (0.16%	  CHOLESTEROL).	  MOUSE	  B	  CELLS	  WERE	  
STAINED	  WITH	  ANTI-­‐B220	  (B	  CELL	  MARKER),	  ANTI-­‐CD138	  (PLASMA	  CELL	  MARKER),	  ANTI-­‐IGM,	  ANTI-­‐IGD,	  
ANTI-­‐CD24,	  ANTI-­‐CD21,	  AND	  ANTI-­‐CD23	  BEFORE	  BEING	  ANALYZED	  BY	  FLOW	  CYTOMETRY.	  THE	  FO	  B	  CELL	  
SUBSET	  WAS	  GATED	  AS	  B220+	  CD138-­‐	  IGMLO	  IGD+	  CD21INT	  CD23+.	  	  SHOWN	  ARE	  THE	  AVERAGE	  
PERCENTAGES	  (+SD)	  FROM	  TWO	  INDEPENDENT	  EXPERIMENTS	  USING	  FOUR	  MICE	  PER	  EXPRESSION	  STRAIN	  (WT	  
AND	  KO).	  10A	  P-­‐VALUES	  (CHOW	  V	  HFD	  LO	  C/HFD	  LO	  C	  V	  HFD	  HI	  C):	  0.001/0.076.	  10B	  P-­‐VALUES	  
(CHOW	  V	  HFD	  LO	  C/HFD	  LO	  C	  V	  HFD	  HI	  C):	  0.016/0.058.	  10C	  P-­‐VALUES	  (CHOW	  WT	  V	  CHOW	  KO/HFD	  
LO	  C	  WT	  V	  HFD	  LO	  C	  KO/HFD	  HI	  C	  WT	  V	  HFD	  HI	  C	  KO):	  0.996/0.847/0.992. ...........................................33	  
FIGURE	  11:	  EFFECTS	  OF	  HIGH	  FAT	  DIET	  ON	  SPLENIC	  MZ	  B	  CELLS	  OF	  WILD	  TYPE	  (A)	  AND	  L1	  KO	  MICE	  (B)	  AFTER	  HIGH	  
FAT	  DIET.	  MICE	  WERE	  FED	  EITHER	  A	  NORMAL	  CHOW	  DIET,	  A	  HIGH	  FAT	  DIET	  WITH	  LOW	  CHOLESTEROL	  (<0.02%	  
CHOLESTEROL)),	  OR	  A	  HIGH	  FAT	  DIET	  WITH	  HIGH	  CHOLESTEROL	  (0.16%	  CHOLESTEROL)	  MOUSE	  B	  CELLS	  WERE	  
STAINED	  WITH	  ANTI-­‐B220	  (B	  CELL	  MARKER),	  ANTI-­‐CD138	  (PLASMA	  CELL	  MARKER),	  ANTI-­‐IGM,	  ANTI-­‐IGD,	  
ANTI-­‐CD24,	  ANTI-­‐CD21,	  AND	  ANTI-­‐CD23	  BEFORE	  BEING	  ANALYZED	  BY	  FLOW	  CYTOMETRY.	  THE	  MZ	  B	  CELL	  
SUBSET	  WAS	  GATED	  AS	  B220+	  CD138-­‐	  IGM+	  IGD-­‐	  CD21+	  CD23LO.	  	  SHOWN	  ARE	  THE	  AVERAGE	  
PERCENTAGES	  (+SD)	  FROM	  TWO	  INDEPENDENT	  EXPERIMENTS	  USING	  FOUR	  MICE	  PER	  EXPRESSION	  STRAIN	  (WT	  
AND	  KO).	  11A	  P-­‐VALUES	  (CHOW	  V	  HFD	  LO	  C/HFD	  LO	  C	  V	  HFD	  HI	  C):	  0.198/0.002.	  11B	  P-­‐VALUES	  
(CHOW	  V	  HFD	  LO	  C/HFD	  LO	  C	  V	  HFD	  HI	  C):	  0.010/0.487.	  11C	  P-­‐VALUES	  (CHOW	  WT	  V	  CHOW	  KO/HFD	  
LO	  C	  WT	  V	  HFD	  LO	  C	  KO/HFD	  HI	  C	  WT	  V	  HFD	  HI	  C	  KO):	  0.003/0.034/0.015. ...........................................35	  
FIGURE	  12:	  EFFECTS	  OF	  HIGH	  FAT	  DIET	  ON	  SPLENIC	  T1	  B	  CELLS	  OF	  WILD	  TYPE	  (A)	  AND	  L1	  KO	  MICE	  (B)	  AFTER	  HIGH	  
FAT	  DIET.	  MICE	  WERE	  FED	  EITHER	  A	  NORMAL	  CHOW	  DIET,	  A	  HIGH	  FAT	  DIET	  WITH	  LOW	  CHOLESTEROL	  (<0.02%	  
CHOLESTEROL)),	  OR	  A	  HIGH	  FAT	  DIET	  WITH	  HIGH	  CHOLESTEROL	  (0.16%	  CHOLESTEROL)	  MOUSE	  B	  CELLS	  WERE	  
STAINED	  WITH	  ANTI-­‐B220	  (B	  CELL	  MARKER),	  ANTI-­‐CD138	  (PLASMA	  CELL	  MARKER),	  ANTI-­‐IGM,	  ANTI-­‐IGD,	  
ANTI-­‐CD24,	  ANTI-­‐CD21,	  AND	  ANTI-­‐CD23	  BEFORE	  BEING	  ANALYZED	  BY	  FLOW	  CYTOMETRY.	  THE	  T1	  B	  CELL	  
SUBSET	  WAS	  GATED	  AS	  B220+	  CD138-­‐	  IGM+	  IGD+	  CD21LO	  CD23+.	  	  SHOWN	  ARE	  THE	  AVERAGE	  
PERCENTAGES	  (+SD)	  FROM	  TWO	  INDEPENDENT	  EXPERIMENTS	  USING	  FOUR	  MICE	  PER	  EXPRESSION	  STRAIN	  (WT	  
AND	  KO).	  12A	  P-­‐VALUES	  (CHOW	  V	  HFD	  LO	  C/HFD	  LO	  C	  V	  HFD	  HI	  C):	  0.205/<0.001.	  12B	  P-­‐VALUES	  
(CHOW	  V	  HFD	  LO	  C/HFD	  LO	  C	  V	  HFD	  HI	  C):	  <0.001/0.886.	  12C	  P-­‐VALUES	  (CHOW	  WT	  V	  CHOW	  KO/HFD	  
LO	  C	  WT	  V	  HFD	  LO	  C	  KO/HFD	  HI	  C	  WT	  V	  HFD	  HI	  C	  KO):	  0.005/0.004/0.006. ...........................................37	  
FIGURE	  13:	  EFFECTS	  OF	  HIGH	  FAT	  DIET	  ON	  SPLENIC	  T2	  B	  CELLS	  OF	  WILD	  TYPE	  (A)	  AND	  L1	  KO	  MICE	  (B)	  AFTER	  HIGH	  
FAT	  DIET.	  	  MICE	  WERE	  FED	  EITHER	  A	  NORMAL	  CHOW	  DIET,	  A	  HIGH	  FAT	  DIET	  WITH	  LOW	  CHOLESTEROL	  (<0.02%	  
CHOLESTEROL)),	  OR	  A	  HIGH	  FAT	  DIET	  WITH	  HIGH	  CHOLESTEROL	  (0.16%	  CHOLESTEROL)	  MOUSE	  B	  CELLS	  WERE	  
STAINED	  WITH	  ANTI-­‐B220	  (B	  CELL	  MARKER),	  ANTI-­‐CD138	  (PLASMA	  CELL	  MARKER),	  ANTI-­‐IGM,	  ANTI-­‐IGD,	  
ANTI-­‐CD24,	  ANTI-­‐CD21,	  AND	  ANTI-­‐CD23	  BEFORE	  BEING	  ANALYZED	  BY	  FLOW	  CYTOMETRY.	  THE	  T2	  B	  CELL	  
SUBSET	  WAS	  GATED	  AS	  B220+	  CD138-­‐	  IGM+	  IGD-­‐	  CD21LO	  CD23+	  CD24LO.	  	  SHOWN	  ARE	  THE	  AVERAGE	  
PERCENTAGES	  (+SD)	  FROM	  TWO	  INDEPENDENT	  EXPERIMENTS	  USING	  FOUR	  MICE	  PER	  EXPRESSION	  STRAIN	  (WT	  
AND	  KO).	  13A	  P-­‐VALUES	  (CHOW	  V	  HFD	  LO	  C/HFD	  LO	  C	  V	  HFD	  HI	  C):	  0.008/0.098.	  13B	  P-­‐VALUES	  
(CHOW	  V	  HFD	  LO	  C/HFD	  LO	  C	  V	  HFD	  HI	  C):	  0.199/0.566.	  13C	  P-­‐VALUES	  (CHOW	  WT	  V	  CHOW	  KO/HFD	  
LO	  C	  WT	  V	  HFD	  LO	  C	  KO/HFD	  HI	  C	  WT	  V	  HFD	  HI	  C	  KO):	  0.013/0.405/0.026. ...........................................39	  
FIGURE	  14:	  EFFECTS	  OF	  HIGH	  FAT	  DIET	  ON	  SPLENIC	  FO	  B	  CELLS	  OF	  WILD	  TYPE	  (A)	  AND	  L1	  KO	  MICE	  (B)	  AFTER	  HIGH	  
FAT	  DIET.	  MICE	  WERE	  FED	  EITHER	  A	  NORMAL	  CHOW	  DIET,	  A	  HIGH	  FAT	  DIET	  WITH	  LOW	  CHOLESTEROL	  (<0.02%	  
CHOLESTEROL)),	  OR	  A	  HIGH	  FAT	  DIET	  WITH	  HIGH	  CHOLESTEROL	  (0.16%	  CHOLESTEROL)	  MOUSE	  B	  CELLS	  WERE	  
STAINED	  WITH	  ANTI-­‐B220	  (B	  CELL	  MARKER),	  ANTI-­‐CD138	  (PLASMA	  CELL	  MARKER),	  ANTI-­‐IGM,	  ANTI-­‐IGD,	  
ANTI-­‐CD24,	  ANTI-­‐CD21,	  AND	  ANTI-­‐CD23	  BEFORE	  BEING	  ANALYZED	  BY	  FLOW	  CYTOMETRY.	  THE	  ISOTYPE	  
SWITCHED	  B	  CELL	  SUBSET	  WAS	  GATED	  AS	  B220+	  CD138-­‐	  IGM-­‐	  IGD-­‐	  CD21+	  CD23LO.	  	  SHOWN	  ARE	  THE	  
AVERAGE	  PERCENTAGES	  (+SD)	  FROM	  TWO	  INDEPENDENT	  EXPERIMENTS	  USING	  FOUR	  MICE	  PER	  EXPRESSION	  
STRAIN	  (WT	  AND	  KO).	  14A	  P-­‐VALUES	  (CHOW	  V	  HFD	  LO	  C/HFD	  LO	  C	  V	  HFD	  HI	  C):	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  14B	  P-­‐
VALUES	  (CHOW	  V	  HFD	  LO	  C/HFD	  LO	  C	  V	  HFD	  HI	  C):	  0.696/0.003.	  14C	  P-­‐VALUES	  (CHOW	  WT	  V	  CHOW	  
KO/HFD	  LO	  C	  WT	  V	  HFD	  LO	  C	  KO/HFD	  HI	  C	  WT	  V	  HFD	  HI	  C	  KO):	  0.950/0.011/0.002. ........................41	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Though the specific chemical and biological components of vaccines used today 
may differ considerably, they all essentially seek a similar result: the successful priming 
of the immune system such that a strong secondary response will be generated upon 
subsequent exposure to the same pathogenic antigen of choice.  The effective nature of 
this secondary response is known as immunological memory.  Immunological memory is 
established through the production and proliferation of memory cells.  B cells and T cells 
are the only well established immune cell types to produce memory subsets [1].  The 
primary focus of my thesis is the memory B cell, whether the generation of these memory 
B cells is affected by the expression of the cell surface protein CD23 and/or a high fat 
diet.  Preliminary data has shown that memory B cells generally have lower CD23 
expression when compared to naïve non-memory cells [2].  Previous studies have shown 
that an over-expression of CD23 (via the use of transgenic mice) reduces the production 
of IgE and IgG antibodies upon secondary exposure [3].  This suggests a role for CD23 in 
down-regulating memory B cell responses.  Data generated from my work not only 
corroborates previous data showing low CD23 expression on the memory B cell 
population, but also shows a decrease in the percentage of memory B cells present in the 
spleen of CD23 transgenic mice.  The central hypothesis of this project is that the CD23 
molecule plays a negative regulatory role in the generation of memory B cell responses 
by either inhibiting the generation of memory B cells or the activation and differentiation 
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of memory B cells into plasma cells.  A mechanistic understanding of CD23’s role in 
memory B cell activation can help to broaden our knowledge of memory B cell activation 
and the secondary immune response. 
The Immune System 
The immune system has two major branches: the innate and the adaptive immune 
systems.  Working with physical barriers like skin and mucosal membranes, the innate 
immune system acts as a rapid second line of defense against potentially harmful 
pathogens.  Neutrophils, macrophages, natural killer cells, and the complement proteins 
are all players of the innate immune system.  These cell types and proteins can act in an 
antigen-nonspecific manner in that they do not recognize any specific antigen expressed 
by pathogens.  Instead, they recognize the more general pathogen-associated molecular 
patterns (PAMPs) [4].  Some of the more common PAMPs include bacterial and fungal 
cell wall components, flagellin, LPS, double stranded RNA, and unmethylated DNA.  In 
addition to rapidly responding to pathogens, the innate immune response can also play an 
important role in alerting and directing the adaptive immune system to the danger 
through antigen presentation and cytokine production [1].  In this way, both the innate 
and adaptive immune systems can work together to clear infections.  The cells of the 
immune system, both innate and adaptive, communicate through the use of specialized 
chemical signals (in the form of secreted cytokines) and cell surface receptors [5].  These 
secreted cytokines can act as signals to other immune cells by binding to specific 
receptors on the surfaces of the cells.  This binding can initiate a cytoplasmic signaling 
cascade that stimulates the cell into performing some specified action [5].  The general 
characteristics of the innate immune system is that it is very quick, but nonspecific, and it 
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responds similarly each time it’s activated.  The adaptive immune system, however, has 
the ability to adjust the level and specificity of its response depending on the type of 
pathogen as well as how often a specific pathogen has been encountered. 
The development of immunological memory is the hallmark of the adaptive 
immune system [1].  Lymphocytes are the major players of adaptive immunity.  Cells of 
the adaptive immune system express antigen receptors on their surfaces.  These antigen 
receptors are members of the immunoglobulin family that can bind to specific epitopes 
present within a particular antigen [6, 7].  The cells of the adaptive immune system use 
these antigen receptors to constantly monitor their surroundings for the presence of 
pathogenic epitopes.  The two key players of this adaptive immune system are T cells and 
B cells. 
T cells are considered to be somewhat like the directors of the adaptive system.  
This cell type has the ability to utilize its antigen receptor (also known as the T cell 
receptor or TCR) to scan other cells for the presence of foreign antigens [1].  All 
nucleated mammalian cells express a group of specialized proteins known as the major 
histocompatibiltiy complexes (MHCs) on their surfaces [8].  There are three different 
classes of MHC molecules present on mammalian cells, but current knowledge suggests 
that only class I MHC (MHC I) and class II MHC (MHC II) are important players in the 
adaptive immune system [1].  The MHC I molecules are responsible for presenting 
protein antigen from the cytoplasm.  The fragmented peptides of the antigens are bound 
to MHC I and then displayed on the cell’s surface.  MHC II molecules, on the other hand, 
are responsible for presenting protein antigen that has been collected extracellularly via 
endocytosis.  Expressed primarily by cells classified as professional antigen presenting 
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cells (APCs), including dendritic cells, macrophages, and B cells, MHC II complexes 
bind fragments of endocytosed extracellular proteins in endosomes and display them at 
the surface of professional APCs.  T cells can use their TCRs to scan antigen presented 
by MHCs [4, 9].  The two major T cell subsets responsible for monitoring cells 
expressing MHCs are the CD4 positive helper T cell and the CD8 positive cytotoxic T 
cell [10].  The CD8 positive T cells are called ‘cytotoxic’ since they have the ability to 
directly kill their targeted cell [10].  Under normal conditions, CD8 positive T cells bind 
specific antigen-loaded MHC I molecules which induces signaling cascades in T cells 
and triggers their killing mechanisms which lead to apoptosis or necrosis of the target cell 
[6].  The CD4 positive T cells are helper cells that play major roles in monitoring and 
regulating the responses of other immune cells.  CD4 positive T cells scan the MHC II 
molecules on the surfaces of professional APCs using their TCRs.  The binding of TCRs 
to antigen-loaded MHC II will activate T cells to secrete cytokines that in turn activate 
antigen presenting cells [4, 9, 11]. 
One of the major contributions of B cells to the adaptive immune system is to 
mediate antigen-specific antibody responses.  B cells scan for antigen using B cell 
receptors (BCRs).  Different from TCRs on T cells, BCRs can directly bind to specific 
antigens without the presentation by MHC molecules [4, 9].  The specificity of BCRs to 
antigen allows them to effectively capture, internalize, process, and eventually present the 
antigen on the B cell surface.  Through presenting antigen bound to MHC II, B cells can 
activate CD4 positive T helper cells, and activated T cells in turn provide essential help 
for B cell activation [11].  Once activated, B cells proliferate and differentiate into 
memory B cells and antibody producing plasma cells [5, 12].  Once differentiated, these 
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plasma cells will continuously secrete antibody specific for their cognate antigen.  The 
additional signals generated from T helper cells to B cells through antigen presentation is 
essential for generating memory B cells and secondary antibody responses. 
The binding of antigen or antigen-MHC complexes to TCRs or BCRs causes 
these surface receptors to oligomerize in lipid rafts [6, 13], which helps to recruit many 
cytoplasmic signaling molecules to the receptors and induces their activation.  The 
activation of these molecules induces signaling cascades which can lead to cell 
proliferation and expansion of lymphocyte clones that are specific for the threat.  For T 
cells, this proliferation leads to the generation of effector, memory, and regulatory T cells 
[14].  For B cells, activation of signaling cascades can result in differentiation of B cells 
into antibody-producing plasma cells [9].  This initial antibody response mainly consists 
of relative low affinity IgM isotype antibodies named as the primary immune response 
[Fig. 1].  These IgM antibodies have the ability to bind antigen with specificity and to 
opsonize their targets.  The resulting effect of the antibody opsonization is the 
neutralization of their secreted toxins [15] and ‘flagging’ of the pathogens for 
complement and immune cell-mediated killing [15].  Antibody opsonized pathogens are 
more efficiently phagocytosed and killed by phagocytotic cells than pathogens that have 
not encountered antibody [16].  In addition, IgM-immobilized pathogens are very 
effective in activating the complement and the innate immune system [15]. 
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Figure	  1:	  Simplified	  model	  of	  B	  cell	  activation	  [17]. 
The B Lymphocyte 
Antibodies are a product of the adaptive immune system.  They are synthesized 
and secreted by plasma cells, the effector subset of B lymphocytes or ‘B cells’ [18].  
During development in the bone marrow, B cells undergo multiple steps of gene-
rearrangement to express a functional BCR [19].  The BCR is a cell surface molecule that 
allows the B cell to bind and recognize its cognate antigen [19-21].  B cells expressing 
BCRs that bind to self antigen in the bone marrow are negatively screened and prevented 
from maturing under normal circumstances [19]. 
Once the immature non self-reactive B cells finally migrate away from the bone 
marrow to the secondary lymphoid tissues, they become known as transitional B cells 
[22].  Transitional B cells receive surviving signals in the secondary lymphoid tissue and 
become naïve mature B cells [22].  Mature B cells that reside in the spleen or lymph 
nodes can be divided into two main populations: follicular B cells (FO) and marginal 
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zone B cells (MZ).  FO B cells are the major subset of B cells in the secondary lymphoid 
tissue and reside within the lymphoid follicles.  FO B cells express low levels of IgM, 
high levels of IgD and CD23, but not CD5 and have the ability to recirculate.  In contrast, 
the MZ B cells usually remain located along the marginal edge of the lymphoid follicle 
and the red pulp of the spleen.  The marginal zone is an area where macrophages and 
dendritic cells also reside.  MZ B cells are non-recirculating, but can be rapidly recruited 
into the early adaptive immune response with the help of T cells [23].  MZ B cells usually 
express high levels of IgM and CD21, but low levels of IgD, and CD23.  Recent studies 
show that MZ B cells play an essential role in transporting antigen into B cell follicles 
[23]. 
B Lymphocyte Activation 
The B cell receptor (BCR) is the central player in B cell activation [19].  The 
BCR consists of two major parts: the antigen-binding and the signaling subunits.  The 
antigen-binding subunit consists of membrane immunoglobulins (mIgs), providing two 
antigen-binding sites in each mIg.  The signaling subunit is comprised of the Igα and Igβ 
heterodimer [Fig. 2].  While all five isotypes of Igs have membrane form, naïve B cells 
express mIgM and mIgD-based BCR.  The Igα and Igβ heterodimer has distinctly longer 
cytoplasmic tails than mIgM [21].  Each of their cytoplasmic tails contains an 
immunoreceptor tyrosine-based activation motif (ITAM).  Upon binding of antigen to the 
BCR, the tyrosine residues of the ITAMs are phosphorylated by Src family kinases [20].  
Phosphorylation of the ITAMs allows for the docking of spleen tyrosine kinase (Syk), a 
Src homology 2 (SH2) domain-containing kinase [21, 24].  Antigen binding also induces 
the phosphorylation of the ITAMs on the BCR co-receptor CD19 [19], which recruits 
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another SH2 domain-containing kinase, phosphatidylinostitol 3-kinase (PI3K).  Though 
recruitment of PI3K via ITAMs on CD19 is considered to be the major mechanism by 
which PI3K locates to the plasma membrane, it has also been suggested to be recruited by 
other mechanisms [19].  Once bound to phosphorylated ITAMs, Syk can associate with 
and phosphorylate adapter proteins such as B-linker protein (BLNK).  The activated 
BLNK protein can then recruit phospholipase Cγ (PLCγ) to the complex.  The 
phosphorylation of PLCγ by Syk partially activates it.  Meanwhile, the activated PI3K 
molecule phosphorylates and converts phosphatidylinositol-3,4-bisphosphate (PIP2) to 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) [19].  This conversion of PIP2 to PIP3 
allows for the recruitment of the Bruton’s tyrosine kinase (Btk) protein to the membrane 
through direct interaction with PIP3.  Once associated with the membrane and in 
proximity of the other signaling molecules, Btk can phosphorylate PLCγ, which in 
combination with the phosphorylation by Syk, activates the PLCγ molecule [19].  
Activated PLCγ can convert PIP2 into diacylglycerol (DAG) and soluble inositol-1,4,5-
trisphosphate (IP3).  IP3 activates calcium flux.  Calcium and DAG activate protein 
kinase C (PKC) that, in turn, activates nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB).  NF-κB is critical for B cell development, maturation, and 
proliferation [25].  Calcium can bind to the serine/threonine phosphatase calcineurin.  
Calcineurin can then dephosphorylate the protein nuclear factor of activated T-cells 
(NFAT), which causes it to translocate into the nucleus where it participates in 
transcriptional activation of genes associated with proliferation [19].  While the signaling 
transduction of the BCR in naïve mature B cells has been extensively studied, the 
mechanisms underlying memory B cell activation remain to be defined. 
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Figure	  2:	  Schematic	  of	  the	  B	  cell	  receptor	  complex	  [21]. 
The BCR activation process is balanced by down regulation to control the level 
and duration of B cell activation.  Malfunctions in these down regulatory mechanisms are 
associated with autoimmune diseases.  A major negative regulatory co-receptor in B cells 
is Fcγ receptor IIB (FcγRIIB).  Upon binding to antibody-antigen immune complexes, 
FcγRIIB can inhibit B cell activation through its downstream signaling molecule SH2-
containing tyrosine phosphatase 1 (SHP-1).  The cytoplasmic tail of FcγRIIB contains the 
inhibitory immunoreceptor tyrosine-based inhibition motifs (ITIMs).  FcγRIIB binds to 
the Fc domain of an IgG-antigen immuno-complex that colligates FcγRIIB with the BCR 
that binds to antigen.  The colliagtion brings the cytoplasmic tails of the Fc receptor and 
the BCR into close proximity causing the ITIMs on the Fc receptor to become 
phosphorylated by Lyn kinase [26].  Once phosphorylated, the ITIMs can recruit 
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inhibitory signaling molecules like SHIP-1 as well as tyrosine phosphatases SHP-1 and 
SHP-2.  SHP-1 and SHP-2 dephosphorylate many of the signaling molecules associated 
with BCR signaling [27].  SHIP converts PIP3 to PIP2, blocking the recruitment of Btk to 
the plasma membrane [28].  CD23 is another Fc binding coreceptor expressed on FO B 
cells, but its role in B cell signaling and activation remain unclear. 
Memory B Cells 
In the presence of cognate antigen and T cell help, B cells undergo rapid 
proliferation, resulting in the formation of very large clusters of B cells known as 
germinal centers [7].  Within the germinal centers, B cells undergo isotype switching 
(typically to the IgG isotype) which determines the immunological function of the 
antibodies their descendant plasma cells will be able to generate [Fig.1].  In the presence 
of T cell help via antigen presentation by B cells and follicular dendritic cells, B cells go 
through somatic hypermutation and affinity maturation, where the variable regions of 
their mIg genes become highly mutated and B cells expressing high affinity antibody are 
selected for survival and differentiation into memory B cells.  Therefore memory B cells 
express isotype switched receptors that have a greater affinity for their cognate antigen 
than naïve B cells [8]. 
The memory B cell is a key component of the adaptive immune system and is 
considered to be the central player in the development of long-term humoral immunity.  
They are long-lived and differentiate into long-lived plasma cells that secrete high 
affinity antibodies upon stimulation [29, 30].  Upon reencountering an antigen, memory 
B cells that were generated from the first antigen encounter mount a rapid and high 
affinity secondary antibody response.  Therefore, a major characteristic that separates 
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memory B cells from their naïve parent cells is their significantly lower threshold for 
activation and rapidly robust proliferative activity [29].  Evidence of these differences 
can be observed during the secondary immune response where the activation and 
proliferation of memory B cells results in the rapid production of antibody-secreting 
plasma cells [29] and differences in serum antibody titers after primary and secondary 
antigen exposure [Fig. 3]. 
	  
Figure	  3:	  Diagram	  displaying	  serum	  antibody	  titer	  after	  primary	  and	  secondary	  immunization	  with	  
generic	  'Antigen	  A'	  [31]. 
The ability to produce memory cells that can rapidly respond to and clear specific 
pathogenic antigens before they are able to do much damage is a very powerful attribute 
of the immune system.  Vaccines developed today attempt to take advantage of this 
process in order to protect us from dangerous pathogens.  The most effective vaccines are 
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those that can induce the development of large numbers of memory cells that can react 
quickly to their target pathogen without causing any adverse effects to the host organism 
or patient.  From a scientific standpoint, it is somewhat surprising how little we know 
conclusively about how memory B cells are generated and activated.  Although several 
studies have identified multiple strategies for stimulating stronger memory B cell 
responses, the underlying molecular mechanisms driving this process still remain unclear 
[32]. 
The CD23/FcεRII Molecule 
The CD23 molecule was originally discovered as an Fc receptor of IgE (FcεRII).  
It is a 45kD type II membrane protein and is expressed by several different cell types, 
most notably activated macrophages, follicular dendritic cells, and B cells [33].  There 
are currently two known isoforms of the molecule expressed in humans: CD23a and 
CD23b.  The two CD23 isoforms differ only by the first 6-7 residues of their cytoplasmic 
N-terminal regions [34].  Current studies show the expression of the CD23a isoform to be 
B cell exclusive [33], however expression of the CD23b isoform can be induced in 
several different cell types including B cells, T cells, monocytes, and dendritic cells [35].  
There is currently only one known isoform of CD23 present in mice, which most closely 
resembles the CD23a human isoform [33].  The CD23 molecule is initially classified as a 
low affinity receptor for IgE, but this only appears to be the case when the molecule 
exists as a monomer [36].  When CD23 becomes oligomerized, its affinity for IgE 
becomes comparable to that of the high affinity IgE receptor, FcεRI [37].  CD23 has been 
suggested to act as a negative regulator of both IgE and IgG responses [33, 34].  Though 
the exact mechanism of this action is not completely understood, it has been shown that 
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binding of IgE to CD23 leads to an inhibitory signaling cascade that is associated with 
down-regulation of IgE responses [36].  Fujiwara et al. [38] found that both the antigen-
specific and overall levels of IgE and IgG were greater during secondary exposure to 
antigen in CD23 deficient mice when compared to wild type mice.  Payet et al. [34], 
using a CD23 transgenic mouse model, found that both the primary and secondary IgE 
and IgG responses were significantly decreased in the mice that over-expressed CD23 
when compared to wild type mice.  Their results further suggested that expression of 
CD23 on FDCs play a key role in down-regulating the IgE response through interactions 
with CD21 on IgE positive B cells [34].  A more recent study shows that CD23 positive 
B cells could bind and effectively transport IgE-bound antigen to FDCs where it is then 
processed and presented to T helper cells [39].  These data clearly support the notion that 
CD23 plays a regulatory role in both IgE and IgG antibody responses through multiple 
mechanisms.  The findings that CD23 expression not only affected the primary response 
but also the secondary immune response imply that this molecule may play a role in the 
activity of memory B cells.  What remains to be addressed is whether CD23 regulates the 
development of memory B cells or differentiation of memory B cells into plasma cells.  It 
is possible that cross-linking of CD23 by immunological complexes containing IgE 
induces inhibitory signals in B cells.  This would help to explain the observation of lower 
antibody titers in mice over-expressing CD23.  This thesis aims to explore these essential 
questions with the hope of shedding light on some of the mechanisms by which humoral 
memory responses are regulated. 
	   14	  
Lipid Metabolism and Immunity 
Recent studies have shown that inflammatory immune responses may play a 
significant role in diseases caused by lipid metabolism disorders like obesity and type II 
diabetes [40-43].  Multiple studies have demonstrated that development of these 
metabolic diseases can be exacerbated by the disruption of the reverse cholesterol 
transporter (RCT) pathway [42].  The RCT pathway is responsible for reducing blood 
plasma cholesterol levels via a high-density lipoprotein (HDL) mechanism.  Upon 
entering a blood vessel with a high concentration of cholesterol, macrophages can take up 
large amounts of the sterol and become immobilized which keeps them in a sustained 
inflammatory state and can lead to lesions associated with vascular plaque buildup [41].  
In addition to inflammation, recent studies have demonstrated a direct link between the 
development of insulin resistance and B cell-mediated autoimmunity in obese mice [42].  
B cells were found to be responsible for high fat diet-induced insulin resistance, the 
production of pathogenic IgG autoantibodies, and activation of pro-inflammatory T cells 
and macrophages in adipose tissues.  This combination subsequently led to insulin 
resistance and glucose intolerance in obese mice. 
The Neimann-Pick C1-Like 1 protein (NPC1L1) is a transmenbrane protein 
associated with lipid metabolism and more specifically with cholesterol transport and 
absorption into the liver and small intestine [44].  In humans, the NPC1L1 protein (L1) is 
primarily expressed in the liver with slightly less expression in the small intestine.  In 
mice, the L1 protein is almost exclusively expressed in the small intestine [44, 45].  In 
studies involving a L1 KO mouse model, it was found that NPC1L1 gene knock out mice 
developed a high level of resistance to hypercholesterolemia after being placed on a high 
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cholesterol diet when compared to wild type [44, 46].  A somewhat similar phenomenon 
is observed in human patients suffering from high cholesterol who are administered 
ezetimibe (a drug designed to target and inhibit the L1 protein).  Multiple studies with 
human patients treated with ezetimibe demonstrate the drug’s effectiveness in lowering 
blood cholesterol levels [47, 48]. 
Studies conducted by Winer et al. [42] suggest that high fat diet-induced obese 
mice developed visceral fat tissue inflammation and symptoms of type II diabetes due, in 
large part, to the activity of B cells.  Their data shows that although pro-inflammatory 
macrophages, T cells, and B cells are all recruited to the fat tissue in obese mice that 
develop disease, B cell deficient obese mice showed no development of disease and 
reductions in proinflammatory cytokines produced by T cells [42].  When serum IgG 
antibodies from symptomatic mice are transferred into B cell deficient obese mice, they 
quickly develop both insulin resistance and glucose intolerance [42].  The development 
of the disease in obese mice could be attenuated through treatments designed to deplete B 
cells [42].  Considering their data, Winer et al. concluded that B cells contribute to the 
development of insulin resistance and glucose intolerance through producing 
autoantibodies and activating T cells in adipose tissues.  However, how disorders of lipid 
metabolism impact on B cell activation and self-tolerance is largely unknown. 
The goal of this research is to explore the role of CD23 in and the impact of high 
fat diet on the generation of memory B cells.  Using CD23 transgenic mice, I examined 
the effect of over expression of CD23 on peripheral B cell subsets.  Using mice fed with a 
high fat diet, I examined whether the high fat diet has any impact on peripheral B cell 
subsets.
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SIGNIFICANCE 
The B cell-mediated antibody response is an essential component of adaptive 
immunity.  Memory B cells are responsible for humoral memory responses.  
Immunological memory is the basis of vaccination.  Because of their longevity, the 
regulation of memory B cell generation and activation is critical for the control of the 
immune response.  Malfunctions in this regulatory mechanism could lead to deficiencies 
in humoral protection against pathogens or the long-term production of autoantibodies 
that are associated with autoimmune diseases and allergic reactions [49, 50].  This could 
lead to the overreaction of the host’s immune system to otherwise harmless antigens in 
the form of chronic allergies or diseases like asthma [30].  Memory B cells that are 
reactive to self antigens could lead to the development of life-threatening auto-immunity 
where the immune system becomes a deadly enemy to the host organism itself [16, 51].  
As was described in the introduction, the activity of B cells and B cell-generated 
autoantibodies has been directly linked to obesity-associated insulin resistance [42].  
Obesity induced diabetes has become epidemic in the United States and many European 
countries and effective intervention is urgently needed.  This is where a more thorough 
understanding of the regulatory mechanisms of memory B cells becomes most valuable. 
My Master thesis research has generated preliminary data for future examination 
of several major questions: does CD23 affect memory B cell development and activation, 
does CD23 impact BCR signaling, and does the proper function of cholesterol 
transporters linked to obesity affect the B cell mediated immune response?  In addressing 
the major questions of this project, we will increase our understanding of the underlying 
mechanisms for the regulation of long-term B cell-mediated immunity.  A more complete 
	   17	  
understanding of these mechanisms could lead to more effective vaccine development 
strategies and advancements in the treatment of B cell-associated autoimmune diseases. 
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METHODS 
Isolation of B cells 
The human B cells were acquired from hPBMCs isolated from leukopak blood 
donations using Ficoll gradient centrifugation and the Miltenyi Biotec™ B cell isolation 
kit along with AutoMACS™.  After successful isolation, the cells were counted, treated 
with a cryopreservation solution containing DMSO, aliquoted into separate vials 
containing approximately 4.0x106 cells/mL, and then stored in liquid nitrogen. 
The mouse B cells were harvested and then isolated from ground mouse spleens 
using Ficoll gradient centrifugation followed by treatment with T cell lysis buffer 
(Thy1.1 antibody and complement proteins).  After a period of panning (37°C; 5.0% 
CO2), the cells were counted and then diluted to an approximate concentration of 2.0x106 
cells/mL.  The cells were then stored at 4°C before use. 
Mouse Models 
To address the role of CD23 in B cell activation, I used both CD23 transgenic and 
knockout mice that were kindly provided by Dr. Daniel H. Conrad from the Department 
of Microbiology and Immunology at the Virginia Commonwealth University in 
Richmond, Virginia.  Wild type Balb/cJ mice (Jackson Laboratory) were used as controls 
for these experiments.  The CD23 transgenic mice used in this study were established 
through use of a vector containing a major histocompatibility heavy chain (IgH) 
enhancer.  Use of this enhancer helps to direct expression of the vector to lymphocytes 
and yields a significant increase in CD23 expression in these target cells [34].  The CD23 
knock out (KO) mice were established through use of a vector designed to replace exons 
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3 and 4 of the Fcer2a gene (CD23) with a neomycin resistance cassette.  All mice 
homozygous for the mutant allele effectively silence CD23 expression [60]. 
To examine the relationship between lipid metabolism and B cell development, I 
used a NPC1L1 knock out (L1 KO) strain of C57BL/6 mice that were graciously 
provided by Dr. Liqing Yu at the Department of Animal and Avian Sciences (ANSC) at 
the University of Maryland at College Park.  Wild type C57BL/6 mice were used as 
controls for these experiments.  The L1 KO mice used for this experiment were 
established through use of a vector designed to disrupt the NPC1L1 gene at the unique 
restriction enzyme site AfeI in exon 2 through use of a neomycin resistance cassette [44]. 
In vitro Activation of B cells 
B cell activation was carried out by stimulating the cells in vitro with 
fluorescently-labeled F(ab’)2 anti-human or anti-mouse IgG+M antibody (15µg/mL).  
The antibody was added to the cell solution at a 1:200 dilution and allowed to incubate in 
a 37°C chamber for 5, 15, and 20min time points.  A 0min time point was used as an 
unstimulated control.  This method of stimulation simulates the interaction between B 
cells and soluble antigen [28]. 
Immunofluorescence Microscopy Analysis 
For the microscopy studies, human B cells were thawed and then allowed to 
adhere to poly lysine-coated microscope slides.  Once the cells had adhered to the slides, 
they were then stimulated utilizing the method described previously while still on the 
slides.  After stimulation at various predetermined time points, the slides with the human 
B cells were removed from the 37°C incubation chamber and treated with FcγR blocker 
at 4°C before being subsequently stained with CD19, CD27, and CD23 antibodies.  After 
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several washing steps with media (DME-BSA), the cells were fixed with a 4% solution of 
paraformaldehyde (PFA) at 4°C.  Phosphate-buffer saline (PBS) was used to wash away 
the residual PFA and then all excess liquid was removed from the slides.  Mounting 
media (ProLong® Gold Antifade Reagent) was then applied and coverslips were 
carefully placed onto the slides.  The slides were sealed using clear nail polish and stored 
in low light conditions at 4-8°C for at least 12 hours before analysis using either the Zeiss 
710 or Leica SP5X confocal microscopes. 
Flow Cytometry Analysis 
In order to address the question of whether or not memory B cells expressed 
CD23, I compared the CD23 surface expression levels between memory B cells and 
naïve B cells using flow cytometry.  The B cells isolated from hPBMCs were initially 
thawed in a 37°C water bath and then treated with FcγR blocker before being stained for 
CD19 (B cell marker), CD27 (human memory B cell marker), and CD23 at 4°C.  
Unstained cell samples as well as samples of cells stained with only a single color were 
used as controls for all experiments involving flow cytometry.  After staining was 
completed, the cells were then washed, fixed, and analyzed using the BD FACSCanto 
flow cytometer.  CD19 and CD27 double positive cells were gated as memory B cells and 
the cells that stained CD19 positive, but CD27 negative were considered naïve B cells.  
The mean fluorescence intensity (MFI) of CD23 of these two populations was then 
determined. 
In order to further address the question of CD23 expression in isotype switched vs 
naïve B cells in mice, cells were isolated as previously described from the spleens of 
CD23 transgenic and wild type Balb/c mice.  The B cells were treated with FcR blocker 
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and then stained for B220 (B cell marker), IgM, IgD, CD23, and CD138 (plasma cell 
marker) at 4°C.  Since there is no known memory B cell marker for mice, both IgM and 
IgD stains were included in order to more clearly visualize the naïve and isotype switched 
populations.  After staining, the cells were washed, fixed, and then analyzed using flow 
cytometry.  Any cells staining positive for CD138 were considered to be of the plasma 
cell subset and were excluded from any further analysis.  Those cells staining positive for 
B220, but negative for both IgM and IgD were considered to be of the isotype switched B 
cell population.  The B cells staining positive for either IgM or IgD or both were counted 
as part of the naïve B cell population.  Each of these populations was then analyzed for 
CD23 expression by determining the MFI. 
To address the question of whether CD23 expression could effect the 
development of different B cell subsets, I compared the relative percentages of the 
subsets present in the spleens of CD23 transgenic, CD23 knock out, and wildtype mice.  
The B cells were isolated from the spleen as was previously described and then treated 
with FcγR blocker before staining for B220, IgM, IgD, CD23, CD21, and CD138.  
Again, those cells that exhibited positive staining for CD138 were not analyzed.  B cells 
that stained negative for both IgM and IgD were counted as isotype switched cells.  The 
follicular subset of B cells (FO) were identified by positive IgM, IgD, and CD23 staining 
coupled with low staining of CD21.  Marginal zone B cells (MZ) were gated via positive 
staining of IgM and CD21, low staining of CD23, and negative staining for IgD.  The T1 
subset of B cells were identified through positive IgM, IgD, and CD23 staining, but low 
CD21 staining.  And the T2 subset of B cells was gated through positive staining of IgM 
and CD23, low staining of CD21, and negative staining for IgD. 
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In order to address the questions raised in the lipid metabolism study, I compared 
the relative percentages of different B cell subsets present in the spleens of L1 KO and 
wild type mice.  The B cells were isolated from the spleen as was previously described 
and then treated with FcγR blocker before staining for B220, IgM, IgD, CD23, CD21, 
and CD138.  Again, any cells staining positive for CD138 were not considered for 
analysis.  Cells that stained negative for both IgM and IgD were counted as isotype 
switched B cells.  Positive IgM, IgD, and CD23 staining coupled with low staining of 
CD21 identified the FO subset of B cells.  MZ B cells were gated via positive staining of 
IgM and CD21, low staining of CD23, and negative staining for IgD.  The T1 subset of B 
cells were identified through positive IgM, IgD, and CD23 staining, but low CD21 
staining.  And finally, the T2 subset of B cells was gated through positive staining of IgM 
and CD23, low staining of CD21, and negative staining for IgD. 
Mouse Diet Treatment 
For the lipid metabolism study, both the L1 KO and wild type mice were placed 
on either a normal chow (Prolab RMH 3000) or synthetic high fat diet (Diet Core of 
Wake Forest University School of Medicine) containing a low (<0.02%) or high 
(~0.16%) cholesterol supplement at 6 weeks of age.  The mice were maintained on their 
respective diets for a total of 18 weeks while their weights were monitored on a weekly 
basis [46].  After 16 weeks of the diet treatment, the food intake of the mice was 
monitored daily for the final 2 weeks of the treatment [46].
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RESULTS 
Do memory B cells alter their levels of CD23 expression? 
In order to address the question of whether or not memory B cells expressed 
CD23, I compared the CD23 surface expression levels between human memory B cells 
(CD19 and CD27 double positive) and human non-memory B cells (CD19 positive only) 
using flow cytometry [Figs. 4a-d].  As was previously described, the human B cells were 
isolated from leukopaks of healthy blood donors.  The mean fluorescence intensity (MFI) 
of CD23 of these two populations was determined.  My results show that the MFI of 
CD23 in the memory B cells was slightly higher than what was seen in the non-memory 
B cells [Fig. 4d] though this difference was not statistically significant (P=0.412). 
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Figure	  4:	  CD23	  expression	  in	  human	  memory	  B	  cells.	  (A-­C)	  Representative	  histograms	  of	  five	  
independent	  experiments	  displaying	  mean	  fluorescence	  intensity	  of	  CD23	  expression	  on	  human	  
memory	  B	  cells	  (Blue)	  and	  human	  non-­memory	  B	  cells	  (Light	  Green).	  Human	  peripheral	  blood	  B	  cells	  
were	  stained	  with	  anti-­CD19	  (B	  cell	  marker),	  anti-­CD27	  (memory	  B	  cell	  marker),	  and	  anti-­CD23	  before	  
analysis	  using	  flow	  cytometry.	  CD19+	  CD27+	  cells	  were	  gated	  as	  memory	  B	  cells	  (Black	  Bar)	  and	  CD19+	  
CD27-­	  cells	  as	  non-­memory	  B	  cells	  (Grey	  Bar).	  (D)	  Shown	  are	  the	  average	  MFI	  values	  (+SD)	  from	  five	  
independent	  experiments	  (P=0.412).	  
In order to further investigate these findings, a similar experiment was conducted 
using Balb/c wild type mice [Figs. 5a-c].  Again, as was previously described, mouse B 
cells were isolated from the spleen.  Since there is currently no known specific surface 
marker for mouse memory B cells, I focused on the subset of isotype switched B cells 
(negative for both IgM and IgD).  Since the development of memory in B cells is 
generally accepted as occurring after isotype switching, choosing this subset seemed 
logical.  The difference in MFI observed in the mice was much more pronounced [Figs. 
5a-b], but its significance was merely borderline-at best (P=0.050).  Also, in contrast to 
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the human B cell data, the isotype switched mouse B cells appear to express less CD23 
than the naïve mouse B cells [Fig. 5c]. 
	  
Figure	  5:	  CD23	  expression	  in	  mouse	  B	  cells.	  Representative	  histograms	  of	  two	  independent	  experiments,	  
displaying	  mean	  fluorescence	  intensity	  of	  CD23	  expression	  on	  (A)	  mouse	  naïve	  B	  cells	  (left	  row	  of	  
histograms)	  and	  (B)	  mouse	  isotype	  switched	  B	  cells	  (right	  row	  of	  histograms).	  	  Splenic	  mouse	  B	  cells	  
were	  stained	  with	  anti-­B220	  (B	  cell	  marker),	  anti-­IgM,	  anti-­IgD,	  anti-­CD138	  (plasma	  cell	  marker),	  and	  
anti-­CD23	  before	  analysis	  with	  flow	  cytometry.	  B220+	  IgM+	  and/or	  IgD+	  cells	  were	  gated	  as	  naïve	  B	  cells	  
and	  B220+	  IgM-­	  IgD-­	  cells	  were	  gated	  as	  isotype	  switched	  B	  cells.	  (C)	  Shown	  are	  the	  average	  MFI	  values	  
(+SD)	  from	  two	  independent	  experiments	  using	  three	  mice	  per	  experiment	  (P=0.050). 
How much do the B cells in CD23 transgenic mice over-express CD23? 
To address the role of CD23 in B cell activation, I used CD23 transgenic mice 
that were kindly provided by Dr. Daniel H. Conrad at Virginia Commonwealth 
University, Richmond, Virginia.  This strain of mice constitutively over-expresses CD23 
[34].  To compare the expression level of CD23 in the transgenic mice with wild type 
mice, splenocytes were harvested from age-matched CD23 transgenic, CD23 KO, and 
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wild type mice and stained for B220 (B cell marker), CD138 (plasma cell marker), IgM, 
IgD, and CD23 before analysis using flow cytometry.  Any cells staining positive for 
CD138 were determined to be of the plasma cell subset and were excluded from further 
analysis.  B220 positive cells were gated as B cells and all events within the forward 
scatter and side scatter range for live cells were considered ‘live cells’.  Analysis of the 
data shows that there was an increase in CD23 expression in the total live cells harvested 
from CD23 transgenic mice when compared to their wild type counterparts [Fig. 6a], but 
that this difference held no statistical significance (P=0.282).  The analysis also showed a 
predictably sharp decrease in CD23 expression (P=0.013) in the CD23 KO mice when 
compared with wild type [Fig. 6a].  And then, somewhat surprisingly, though the CD23 
transgenic mice showed higher expression of this surface protein over their wild type 
counterparts [Fig. 6a], the difference was not statistically significant (P=0.077).  In B 
cells harvested from the CD23 transgenic mice, there was also an increase in CD23 
expression when compared to their wild type counterparts [Fig. 6b].  Similar to the results 
observed for the total live cells, however, the difference of expression between the 
transgenic mouse B cells and the wild type mouse B cells held no statistical significance 
(P=0.250).  Again, similar to the results of the total live cell analysis, there was a sharp 
decrease in CD23 expression (P=0.013) in the CD23 KO mice when compared with wild 
type [Fig. 6b].  Finally, almost identical to the total live cell data, the CD23 transgenic 
mice showed higher expression of this surface protein over their wild type counterparts 
[Fig. 6b], but the difference was not statistically significant (P=0.062). 
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Figure	  6:	  Comparison	  of	  CD23	  expression	  in	  total	  (A)	  live	  cells	  and	  (B)	  B	  cells	  only.	  Mouse	  splenocytes	  
were	  stained	  with	  anti-­B220	  (B	  cell	  marker),	  anti-­CD138	  (plasma	  cell	  marker),	  and	  anti-­CD23	  before	  
analysis	  using	  flow	  cytometry.	  B220+	  CD138-­	  cells	  were	  gated	  as	  B	  cells	  and	  live	  cells	  are	  gated	  based	  on	  
the	  forward	  scatter	  (FSC)	  and	  side	  scatter	  (SSC).	  Shown	  are	  the	  average	  MFI	  values	  (+SD)	  from	  two	  
independent	  experiments	  using	  three	  mice	  per	  expression	  strain	  (Wt,	  Tg,	  and	  KO).	  6A	  P-­Values	  (Wt	  v	  
Tg/Wt	  v	  KO/Tg	  v	  KO):	  0.282/0.013/0.077.	  6B	  P-­Values	  (Wt	  v	  Tg/Wt	  v	  KO/	  Tg	  v	  KO):	  0.250/0.013/0.062.	  
Wt:	  wild	  type	  mice;	  Tg:	  CD23	  transgenic	  mice;	  KO:	  CD23	  knock	  out	  mice. 
Does CD23 over-expression in CD23 transgenic mice affect B cell subsets in the 
spleen? 
The over-expression of CD23 has been shown to influence the humoral immune 
response in mice [34].  Here, I examined the percentages of B cell subsets present in the 
spleens of CD23 transgenic mice and compared them to the same B cell subsets in the 
spleens of wild type mice.  The splenocytes were stained for B220, CD138, IgM, IgD, 
CD24, CD21, and the CD23 molecule and analyzed using flow cytometry.  The five 
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different B cell subsets that were observed and for which data was analyzed are as 
follows: follicular B cells (FO), marginal zone B cells (MZ), transitional 1 B cells (T1), 
transitional 2 B cells (T2), and isotype switched B cells.  All cells staining positive for 
B220 were considered to be B cells.  Any cells showing positive staining for CD138 were 
determined to be plasma cells and were excluded from any subsequent analysis.  The FO 
B cell subset was defined as double positive for IgM and IgD, CD23 positive, CD24 low, 
and CD21 low.  The MZ B cell subset was defined as double positive for IgM and CD21, 
CD23 low, CD24 positive, and IgD negative.  The T1 B cell subset was defined as double 
positive for IgM and IgD, CD23 negative, CD21 low, and CD24 positive.  The T2 B cell 
subset was defined as double positive for IgM and CD23, CD24 low, CD21 low, and IgD 
negative.  The isotype switched B cell subset was defined as CD21 positive, CD23 low, 
CD24 low, and double negative for IgM and IgD.  The resulting data showed a slight 
increase (P=0.043) in the percentage of isotype switched B cells in CD23 transgenic mice 
when compared to the wild type mice [Fig. 8]. There was also a significant increase in the 
percentage of MZ [Fig. 7b] and T1 [Fig. 7c] B cells present in the spleens of CD23 KO 
mice when compared to the CD23 transgenic mice (P=0.033 and 0.011, respectively).  
After analyzing all the data, there were no differences in population observed for either 
the FO or the T2 B cell subsets when comparing between the CD23 transgenic, CD23 
KO, and wild type mice [Figs. 7a, d]. 
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Figure	  7:	  Effect	  of	  CD23	  over-­expression	  on	  B	  cell	  subsets	  in	  the	  spleen.	  	  Mouse	  B	  cells	  were	  stained	  with	  
anti-­B220	  (B	  cell	  marker),	  anti-­CD138	  (plasma	  cell	  marker),	  anti-­IgM,	  anti-­IgD,	  anti-­CD24,	  anti-­CD21,	  
and	  anti-­CD23	  before	  being	  analyzed	  by	  flow	  cytometry.	  	  (A)	  The	  follicular	  B	  cell	  subset	  (FO)	  was	  gated	  
as	  B220+	  CD138-­IgMlo	  IgD+	  CD23+	  CD21Int	  (Green	  Bars),	  (B)	  the	  marginal	  zone	  B	  cell	  subset	  (MZ)	  was	  
gated	  as	  B220+	  CD138-­	  IgMhi	  IgD-­	  CD23lo	  CD21hi	  (Maroon	  Bars),	  (C)	  the	  transitional	  1	  B	  cell	  subset	  was	  
gated	  as	  B220+	  CD138-­	  IgM+	  IgD+	  CD21lo	  CD23+	  (Blue	  Bars),	  and	  (D)	  the	  transitional	  2	  B	  cell	  subset	  was	  
gated	  as	  B220+	  CD138-­	  IgM+	  IgD-­	  CD21lo	  CD23+	  (Grey	  Bars).	  Shown	  are	  the	  average	  percentages	  (+SD)	  
from	  two	  independent	  experiments	  using	  three	  mice	  per	  expression	  strain	  (Wt,	  Tg,	  and	  KO).	  7A	  P-­Values	  
(Wt	  v	  Tg/Wt	  v	  KO/Tg	  v	  KO):	  0.755/0.179/0.096.	  7B	  P-­Values	  (Wt	  v	  Tg/Wt	  v	  KO/Tg	  v	  KO):	  
0.371/0.090/0.033.	  7C	  P-­Values	  (Wt	  v	  Tg/Wt	  v	  KO/Tg	  v	  KO):	  0.460/0.645/0.011.	  7D	  P-­Values	  (Wt	  v	  
Tg/Wt	  v	  KO/Tg	  v	  KO):	  0.496/0.145/0.791.	  
	  
Figure	  8:	  Effect	  of	  CD23	  over-­expression	  on	  the	  isotype	  switched	  B	  cell	  subset	  in	  the	  spleen.	  Mouse	  B	  
cells	  were	  stained	  with	  anti-­B220	  (B	  cell	  marker),	  anti-­CD138	  (plasma	  cell	  marker),	  anti-­IgM,	  anti-­IgD,	  
anti-­CD24,	  anti-­CD21,	  and	  anti-­CD23	  before	  being	  analyzed	  by	  flow	  cytometry.	  The	  Isotype	  switched	  B	  
cell	  subset	  was	  gated	  as	  B220+	  CD138-­	  IgM-­	  IgD-­	  CD21+	  CD23lo.	  	  Shown	  are	  the	  average	  percentages	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(+SD)	  from	  two	  independent	  experiments	  using	  three	  mice	  per	  expression	  strain	  (Wt,	  Tg,	  and	  KO).	  P	  
values	  (Wt	  v	  Tg/Wt	  v	  KO/Tg	  v	  KO):	  0.043/0.352/0.243. 
Does CD23 co-cluster with B cell receptor in response to antigen stimulation? 
BCR self-aggregation and cap formation has been shown to play crucial roles in B 
cell activation [28].  To explore whether the CD23 molecule plays a role in BCR 
activation, I analyzed the cellular distribution of CD23 in relation to the distribution of 
BCR after stimulation with soluble antigen.  Human B cells were incubated in a 37°C 
chamber with fluorescently-labeled F(ab’)2 fragment of anti-IgG+M antibody for 0, 5, 15, 
and 20min time points.  After the stimulation period, the B cells were stained with 
fluorescently-labeled antibodies against CD19, CD27 and CD23 at 4°C.  After fixation, 
the cells were mounted to poly-lysine slides and analyzed using confocal microscopy.  
Analysis of these confocal images suggests that surface CD23 can co-cluster with the 
BCR on stimulated cells [Fig. 9].  In un-stimulated cells (0min time point), neither the 
BCR nor the CD23 molecule clustered on the cell surface [Fig. 9].  This apparent co-
clustering could either be coincidental or it could imply a role for CD23 in antigen-
induced BCR aggregation and/or signaling.  Though an exact cause for this co-clustering 
has not yet been elucidated, its pattern seems similar to the inhibitory mechanism that 
FcγRIIb utilizes to suppress B cell activation [26, 52, 53].  Since CD23 (FcεRII) also 
belongs to the class of surface molecules known as Fc receptors, and has been previously 
implicated to play an important part in down-regulating the IgE response [3, 37, 54-56], it 
would not be too far a stretch to think that this co-clustering is indicative of a role for this 
molecule in B cell activation. 
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Figure	  9:	  The	  surface	  distribution	  of	  CD23	  in	  stimulated	  and	  un-­stimulated	  human	  B	  cells.	  B	  cells	  were	  
treated	  with	  fluorescently-­labeled	  anti-­IgG+M	  F(ab’)2	  antibodies	  to	  simulate	  interactions	  with	  soluble	  
antigen	  for	  5,	  10,	  15,	  and	  20	  minutes	  in	  a	  37°C	  incubation	  chamber.	  	  Cells	  incubated	  for	  0	  minutes	  were	  
used	  as	  un-­stimulated	  control	  samples.	  	  After	  stimulation,	  the	  cells	  were	  immediately	  transferred	  to	  4°C	  
conditions	  and	  stained	  with	  fluorescently-­labeled	  anti-­CD19,	  anti-­CD27,	  and	  anti-­CD23	  antibodies.	  Cells	  
were	  fixed	  with	  4%	  paraformaldehyde	  (PFA)	  solution	  mixed	  in	  non-­sterile	  phosphate	  buffered	  saline	  
(PBS).	  B	  cell	  receptor	  is	  represented	  in	  red	  and	  CD23	  is	  represented	  in	  green.	  Shown	  are	  representative	  
images	  from	  five	  experiments. 
Does high fat diet affect the development of peripheral B cells? 
To examine the affect of diet-induced obesity and cholesterol on the development 
of B cells, I isolated B cells from the spleens of cholesterol transporter Neimann-Pick C1-
Like 1 protein (NPC1L1) deficient and wild type mice.  The mice had been placed on 
either normal chow (Prolab RMH 3000) or high fat diet (Diet Core of Wake Forest 
University School of Medicine) with a relatively high (~0.16%) or low level of 
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cholesterol (<0.02%) for 18 weeks [46].  The isolated B cells were then stained for the 
surface markers for different subsets of peripheral B cells, including B220, IgM, IgD, 
CD23, CD24, CD21, and CD138 before analysis using flow cytometry.  The 5 different B 
cell subsets that were observed and for which data was analyzed are as follows: FO B 
cells, MZ B cells, T1 B cells, T2 B cells, and isotype switched B cells.  All cells staining 
positive for B220 were considered to be B cells.  Similar to the previous CD23 study, any 
cells showing positive staining for CD138 were determined to be plasma cells and were 
excluded from any subsequent analysis.  The FO B cell subset was defined as double 
positive for IgM and IgD, CD23 positive, and CD21 low.  The MZ B cell subset was 
defined as double positive for IgM and CD21, CD23 low, CD24 positive, and IgD 
negative.  The T1 B cell subset was defined as double positive for IgM and IgD, CD23 
positive, CD21 low, and CD24 positive.  The T2 B cell subset was defined as double 
positive for IgM and CD23, CD24 low, CD21 low, and IgD negative.  The isotype 
switched B cell subset was defined as CD21 positive, CD23 low, CD24 low, and double 
negative for IgM and IgD. 
The resulting data showed a significant increase (P=0.001) in the percentage of 
FO B cells present in the spleens of wild type mice fed the high fat diet with low 
cholesterol compared to that in wild type mice fed the chow diet [Fig. 10a].  There 
appeared to be no difference (P=0.076) in the percentage of FO B cells in the spleens of 
wild type mice fed with the high fat diet with low cholesterol when compared to those fed 
with the high cholesterol diet [Fig. 10a].  In L1 KO mice, there was also a significant 
increase (P=0.016) in the percentage of FO B cells present in the spleens of mice fed with 
the high fat/low cholesterol diet when compared to those fed the normal chow diet [Fig. 
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10b].  Although there appeared to be a slight increase in the percentage of FO B cells 
present in the spleens of L1 KO mice fed the high cholesterol diet over the low 
cholesterol diet [Fig. 10b], the data reflected no significance (P=0.058).  When directly 
comparing the percentages of FO B cells present in the spleens of L1 KO mice against 
those present in wild type mice fed the same diet regimen, there were no significant 
differences [Fig. 10c]. 
	  
Figure	  10:	  Effects	  of	  high	  fat	  diet	  on	  splenic	  FO	  B	  cells	  of	  wild	  type	  (A)	  and	  L1	  KO	  mice	  (B)	  after	  high	  fat	  
diet.	  Mice	  were	  fed	  either	  a	  normal	  chow	  diet,	  a	  high	  fat	  diet	  with	  low	  cholesterol	  (<0.02%	  cholesterol)),	  
or	  a	  high	  fat	  diet	  with	  high	  cholesterol	  (0.16%	  cholesterol).	  Mouse	  B	  cells	  were	  stained	  with	  anti-­B220	  
(B	  cell	  marker),	  anti-­CD138	  (plasma	  cell	  marker),	  anti-­IgM,	  anti-­IgD,	  anti-­CD24,	  anti-­CD21,	  and	  anti-­
CD23	  before	  being	  analyzed	  by	  flow	  cytometry.	  The	  FO	  B	  cell	  subset	  was	  gated	  as	  B220+	  CD138-­	  IgMlo	  
IgD+	  CD21Int	  CD23+.	  	  Shown	  are	  the	  average	  percentages	  (+SD)	  from	  two	  independent	  experiments	  
using	  four	  mice	  per	  expression	  strain	  (Wt	  and	  KO).	  10A	  P-­Values	  (Chow	  v	  HFD	  Lo	  C/HFD	  Lo	  C	  v	  HFD	  Hi	  
C):	  0.001/0.076.	  10B	  P-­Values	  (Chow	  v	  HFD	  Lo	  C/HFD	  Lo	  C	  v	  HFD	  Hi	  C):	  0.016/0.058.	  10C	  P-­Values	  (Chow	  
Wt	  v	  Chow	  KO/HFD	  Lo	  C	  Wt	  v	  HFD	  Lo	  C	  KO/HFD	  Hi	  C	  Wt	  v	  HFD	  Hi	  C	  KO):	  0.996/0.847/0.992.	  
When looking at the relative percentages of MZ B cells present in the spleens of 
mice fed the high fat/low cholesterol diet with those fed the normal chow diet [Fig. 11a], 
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there appeared to be no difference (P=0.198).  The difference between those wild type 
mice fed the low cholesterol diet versus those fed the high cholesterol diet [Fig. 11a], 
however, was rather apparent (P=0.002).  Interestingly, the L1 KO mice fed the high 
fat/low cholesterol diet showed a significant increase (P=0.010) in the percentage of MZ 
B cells present in the spleens over those fed the chow diet [Fig. 11b].  In the L1 KO mice 
fed either the high fat diet with low cholesterol or high cholesterol [Fig. 11b], there 
appeared to be no difference in the percentage of MZ B cells present in the spleens 
(P=0.487). 
When directly comparing the MZ B cell percentages in the spleens of L1 KO 
mice against those of wild type mice fed the same diet, there were significant differences 
observed [Fig. 11c].  Interestingly, when fed the normal chow diet, the L1 KO mice 
appeared to have significantly less MZ B cells present in the spleen when compared to 
wild type (P=0.003).  Similarly, the L1 KO mice fed the high fat/high cholesterol diet 
also showed a significantly smaller (P=0.015) percentage of spleen MZ B cells when 
compared to their wild type counterparts who were fed the same diet [Fig. 11c].  By 
contrast, when both strains of mice were fed the high fat/low cholesterol diet [Fig. 11c], 
the L1 KO mice had a greater percentage of splenic MZ B cells (P=0.034). 
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Figure	  11:	  Effects	  of	  high	  fat	  diet	  on	  splenic	  MZ	  B	  cells	  of	  wild	  type	  (A)	  and	  L1	  KO	  mice	  (B)	  after	  high	  fat	  
diet.	  Mice	  were	  fed	  either	  a	  normal	  chow	  diet,	  a	  high	  fat	  diet	  with	  low	  cholesterol	  (<0.02%	  cholesterol)),	  
or	  a	  high	  fat	  diet	  with	  high	  cholesterol	  (0.16%	  cholesterol)	  Mouse	  B	  cells	  were	  stained	  with	  anti-­B220	  (B	  
cell	  marker),	  anti-­CD138	  (plasma	  cell	  marker),	  anti-­IgM,	  anti-­IgD,	  anti-­CD24,	  anti-­CD21,	  and	  anti-­CD23	  
before	  being	  analyzed	  by	  flow	  cytometry.	  The	  MZ	  B	  cell	  subset	  was	  gated	  as	  B220+	  CD138-­	  IgM+	  IgD-­	  
CD21+	  CD23lo.	  	  Shown	  are	  the	  average	  percentages	  (+SD)	  from	  two	  independent	  experiments	  using	  four	  
mice	  per	  expression	  strain	  (Wt	  and	  KO).	  11A	  P-­Values	  (Chow	  v	  HFD	  Lo	  C/HFD	  Lo	  C	  v	  HFD	  Hi	  C):	  
0.198/0.002.	  11B	  P-­Values	  (Chow	  v	  HFD	  Lo	  C/HFD	  Lo	  C	  v	  HFD	  Hi	  C):	  0.010/0.487.	  11C	  P-­Values	  (Chow	  Wt	  
v	  Chow	  KO/HFD	  Lo	  C	  Wt	  v	  HFD	  Lo	  C	  KO/HFD	  Hi	  C	  Wt	  v	  HFD	  Hi	  C	  KO):	  0.003/0.034/0.015. 
Looking at the transitional B cells, we see no significant difference (P=0.205) in 
the percentage of spleen T1 B cells in wild type mice fed the high fat/low cholesterol diet 
over those fed the normal chow diet [Fig. 12a].  Interestingly, wild type mice fed the high 
fat/high cholesterol diet showed a dramatically smaller percentage (P<0.001) of T1 B 
cells present in the spleen when compared to mice fed the high fat/low cholesterol diet 
[Fig. 12a].  The L1 KO mice fed the high fat/low cholesterol diet showed a pronounced 
decrease (P<0.001) in spleen T1 B cells when compared to those fed the normal chow 
diet [Fig. 12b].  However, when analyzing the percentages of T1 B cells present in the L1 
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KO mice fed either the high fat/high cholesterol or low cholesterol diet [Fig. 12b], no 
significant difference was observed (P=0.886). 
When directly comparing the T1 B cell percentages in the spleens of L1 KO mice 
against those of wild type mice fed the same diet, there were significant differences 
observed [Fig. 12c].  The L1 KO mice fed the normal chow diet appeared to have a larger 
percentage (P=0.005) of T1 B cells present in their spleens when compared to wild type 
fed the same diet [Fig. 12c].  The L1 KO mice fed the high fat/high cholesterol diet also 
showed a higher percentage (P=0.004) of T1 B cells present in the spleen over wild type 
mice fed the same diet [Fig. 12c].  In contrast, wild type mice fed the high fat/low 
cholesterol diet appeared to have a larger percentage (P=0.006) of splenic T1 B cells 
when compared to L1 KO mice fed the same diet [Fig. 12c]. 
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Figure	  12:	  Effects	  of	  high	  fat	  diet	  on	  splenic	  T1	  B	  cells	  of	  wild	  type	  (A)	  and	  L1	  KO	  mice	  (B)	  after	  high	  fat	  
diet.	  Mice	  were	  fed	  either	  a	  normal	  chow	  diet,	  a	  high	  fat	  diet	  with	  low	  cholesterol	  (<0.02%	  cholesterol)),	  
or	  a	  high	  fat	  diet	  with	  high	  cholesterol	  (0.16%	  cholesterol)	  Mouse	  B	  cells	  were	  stained	  with	  anti-­B220	  (B	  
cell	  marker),	  anti-­CD138	  (plasma	  cell	  marker),	  anti-­IgM,	  anti-­IgD,	  anti-­CD24,	  anti-­CD21,	  and	  anti-­CD23	  
before	  being	  analyzed	  by	  flow	  cytometry.	  The	  T1	  B	  cell	  subset	  was	  gated	  as	  B220+	  CD138-­	  IgM+	  IgD+	  
CD21lo	  CD23+.	  	  Shown	  are	  the	  average	  percentages	  (+SD)	  from	  two	  independent	  experiments	  using	  four	  
mice	  per	  expression	  strain	  (Wt	  and	  KO).	  12A	  P-­Values	  (Chow	  v	  HFD	  Lo	  C/HFD	  Lo	  C	  v	  HFD	  Hi	  C):	  
0.205/<0.001.	  12B	  P-­Values	  (Chow	  v	  HFD	  Lo	  C/HFD	  Lo	  C	  v	  HFD	  Hi	  C):	  <0.001/0.886.	  12C	  P-­Values	  (Chow	  
Wt	  v	  Chow	  KO/HFD	  Lo	  C	  Wt	  v	  HFD	  Lo	  C	  KO/HFD	  Hi	  C	  Wt	  v	  HFD	  Hi	  C	  KO):	  0.005/0.004/0.006. 
Continuing with the transitional B cells, we can see a clear decrease (P=0.008) in 
the percentage of T2 B cells present in the spleens of wild type mice fed the high fat/low 
cholesterol diet when compared to wild type mice fed the normal chow diet [Fig. 13a].  A 
difference in the percentages of T2 B cells could not be observed (P=0.098), however, in 
the spleens of wild type mice fed either the high fat/high cholesterol diet when compared 
to those fed the high fat/low cholesterol diet [Fig. 13a].  L1 KO mice fed either the high 
fat/low cholesterol diet or the normal chow diet showed no difference (P=0.199) in the 
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percentage of T2 B cells present in the spleen [Fig. 13b].  Similarly, the L1 KO mice fed 
either the high fat/high cholesterol or high fat/low cholesterol diet showed no difference 
(P=0.566) in spleen T2 B cell percentages [Fig. 13b]. 
When directly comparing the percentage of T2 B cells in the spleens of L1 KO 
mice fed the normal chow diet against those of wild type mice fed the same diet, there 
was a significant decrease observed (P=0.013) for the L1 KO mice [Fig. 13c].  There was 
also a decrease in the percentage (P=0.026) of T2 B cells observed in the spleens of L1 
KO mice fed the high fat/high cholesterol diet when compared to their wild type 
counterparts that were fed the same diet [Fig. 13c].  When comparing the percentages of 
T2 B cells in the spleens of L1 KO mice fed the high fat/low cholesterol diet with wild 
type mice fed the same diet [Fig. 13c], there were no differences observed (P=0.405). 
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Figure	  13:	  Effects	  of	  high	  fat	  diet	  on	  splenic	  T2	  B	  cells	  of	  wild	  type	  (A)	  and	  L1	  KO	  mice	  (B)	  after	  high	  fat	  
diet.	  	  Mice	  were	  fed	  either	  a	  normal	  chow	  diet,	  a	  high	  fat	  diet	  with	  low	  cholesterol	  (<0.02%	  cholesterol)),	  
or	  a	  high	  fat	  diet	  with	  high	  cholesterol	  (0.16%	  cholesterol)	  Mouse	  B	  cells	  were	  stained	  with	  anti-­B220	  (B	  
cell	  marker),	  anti-­CD138	  (plasma	  cell	  marker),	  anti-­IgM,	  anti-­IgD,	  anti-­CD24,	  anti-­CD21,	  and	  anti-­CD23	  
before	  being	  analyzed	  by	  flow	  cytometry.	  The	  T2	  B	  cell	  subset	  was	  gated	  as	  B220+	  CD138-­	  IgM+	  IgD-­	  
CD21lo	  CD23+	  CD24lo.	  	  Shown	  are	  the	  average	  percentages	  (+SD)	  from	  two	  independent	  experiments	  
using	  four	  mice	  per	  expression	  strain	  (Wt	  and	  KO).	  13A	  P-­Values	  (Chow	  v	  HFD	  Lo	  C/HFD	  Lo	  C	  v	  HFD	  Hi	  
C):	  0.008/0.098.	  13B	  P-­Values	  (Chow	  v	  HFD	  Lo	  C/HFD	  Lo	  C	  v	  HFD	  Hi	  C):	  0.199/0.566.	  13C	  P-­Values	  (Chow	  
Wt	  v	  Chow	  KO/HFD	  Lo	  C	  Wt	  v	  HFD	  Lo	  C	  KO/HFD	  Hi	  C	  Wt	  v	  HFD	  Hi	  C	  KO):	  0.013/0.405/0.026. 
After analyzing the percentage of isotype switched B cells present in the spleen, 
there was no significant difference observed (P=0.208) when comparing wild type mice 
fed either the high fat/low cholesterol or normal chow diet [Fig. 14a].  There was, 
however, an increase in the percentage (P=0.006) of splenic isotype switched B cells 
observed in wild type mice fed the high fat/high cholesterol diet over the wild type mice 
fed the high fat/low cholesterol diet [Fig. 14a].  For the L1 KO mice, there was no 
difference observed (P=0.696) in the percentage of isotype switched B cells present in the 
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spleen of mice fed the high fat/low cholesterol diet when compared to L1 KO mice that 
were fed the normal chow diet [Fig. 14b].  Interestingly, the L1 KO mice that were fed 
the high fat/high cholesterol diet showed a marked decrease (P=0.003) in the percentage 
of splenic isotype switched B cells when compared to L1 KO mice that were fed the high 
fat/low cholesterol diet [Fig. 14b]. 
When directly comparing the isotype switched B cell percentages in the spleens of 
L1 KO mice fed the normal chow diet against those of wildtype mice fed the same diet 
[Fig. 14c], there were no significant differences observed (P=0.950).  There was a 
significant decrease (P=0.011) in the percentage of isotype switched B cells observed in 
the spleens of the L1 KO mice fed the high fat/high cholesterol diet when compared to 
wild type mice fed the same diet [Fig. 14c].  Interestingly, when comparing the 
percentages of isotype switched B cells present in the spleens of mice fed the same high 
fat/low cholesterol diet, it was found that the L1 KO mice had a higher percentage 
(P=0.002) of this B cell subset than their wild type counterparts [Fig. 14c]. 
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Figure	  14:	  Effects	  of	  high	  fat	  diet	  on	  splenic	  FO	  B	  cells	  of	  wild	  type	  (A)	  and	  L1	  KO	  mice	  (B)	  after	  high	  fat	  
diet.	  Mice	  were	  fed	  either	  a	  normal	  chow	  diet,	  a	  high	  fat	  diet	  with	  low	  cholesterol	  (<0.02%	  cholesterol)),	  
or	  a	  high	  fat	  diet	  with	  high	  cholesterol	  (0.16%	  cholesterol)	  Mouse	  B	  cells	  were	  stained	  with	  anti-­B220	  (B	  
cell	  marker),	  anti-­CD138	  (plasma	  cell	  marker),	  anti-­IgM,	  anti-­IgD,	  anti-­CD24,	  anti-­CD21,	  and	  anti-­CD23	  
before	  being	  analyzed	  by	  flow	  cytometry.	  The	  isotype	  switched	  B	  cell	  subset	  was	  gated	  as	  B220+	  CD138-­	  
IgM-­	  IgD-­	  CD21+	  CD23lo.	  	  Shown	  are	  the	  average	  percentages	  (+SD)	  from	  two	  independent	  experiments	  
using	  four	  mice	  per	  expression	  strain	  (Wt	  and	  KO).	  14A	  P-­Values	  (Chow	  v	  HFD	  Lo	  C/HFD	  Lo	  C	  v	  HFD	  Hi	  
C):	  0.208/0.006.	  14B	  P-­Values	  (Chow	  v	  HFD	  Lo	  C/HFD	  Lo	  C	  v	  HFD	  Hi	  C):	  0.696/0.003.	  14C	  P-­Values	  (Chow	  
Wt	  v	  Chow	  KO/HFD	  Lo	  C	  Wt	  v	  HFD	  Lo	  C	  KO/HFD	  Hi	  C	  Wt	  v	  HFD	  Hi	  C	  KO):	  0.950/0.011/0.002. 
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Table	  1:	  Splenic	  B	  cell	  subset	  percentages	  (±SD)	  observed	  in	  wild	  type	  mice	  after	  various	  diets.	  
	  
Table	  2:	  Splenic	  B	  cell	  subset	  percentages	  (±SD)	  observed	  in	  NPC1L1	  knock	  out	  mice	  after	  various	  diets.	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SUMMARY OF PRELIMINARY DATA 
In summary, the data generated suggests that isotype switched B cells down-
regulate expression of CD23 when compared to naïve B cells [Fig. 5c].  The down-
regulation of this inhibitory molecule potentially lowers the activation threshold of 
memory B cells.  Utilizing the CD23 transgenic mouse model, it was found that over-
expression of CD23 slightly increased the percentage of isotype switched B cells present 
in the spleen [Fig. 8], implying a possible role for CD23 expression in isotype switching.  
It is also worth noting that both the MZ and the T1 B cell populations were significantly 
increased in the CD23 KO mice [Figs. 7b, 7c].  Additionally, the human B cell data 
shows that CD23 clusters with BCR after in vitro stimulation with soluble antigen, 
suggesting the possible involvement by CD23 in BCR activation [Fig. 9]. 
In the study involving diet-induced obese mice, the data generated suggests that a 
diet high in fat has the ability to stimulate the development of follicular B cells in the 
spleen while somehow suppressing the development of B cells to the transitional stage 
[Figs. 10, 12, 13, Table 1, Table 2, and Table 3].  This transitional B cell decrease could 
be due to the increased maturation and subsequent migration into the splenic follicles 
induced by the high fat diet.  It is also important to note that wild type mice fed a diet 
high in fat and cholesterol showed an increase in the amount of isotype switched B cells 
present in the spleen, which suggests that a high fat/high cholesterol diet can promote B 
cell isotype switching and possibly memory B cell development [Fig. 14, Table 1].  
Interestingly, NPC1L1 knock out mice fed the same diet showed a decrease in isotype 
switched B cells, which suggests that the cholesterol transporter may somehow play a 
role in B cell isotype switching [Fig. 14, Table 2]. 
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Analysis of B cell development in mice fed with different diets suggests that the 
high fat diet somehow stimulates an increase in FO B cells in both the wild type and L1 
KO mice regardless of the level of cholesterol [Figs. 10a, 10b].  This data appears to be 
consistent with recent studies suggesting that diets high in fat can stimulate immune 
responses [57-59].  The data also shows that the high fat diet stimulates an increase in 
MZ B cells when coupled with low cholesterol in wild type mice [Fig. 11a], but in the L1 
KO mice an increase was seen in those fed the high fat diet regardless of the cholesterol 
content [Fig. 11b].  This data also seems to be consistent with generation of some form of 
low-level immune response, but interestingly, wild type mice fed a high fat/low 
cholesterol diet did not generate a change in splenic MZ B cells when compared to those 
fed the normal chow diet [Fig. 11a].  The amount of T1 B cells appears to decrease when 
wild type mice are fed the high fat/high cholesterol diet [Fig. 12a], but the percentage of 
this same B cell subset only decreases in L1 KO mice when fed the high fat/low 
cholesterol diet [Fig. 12b].  The percentage of T2 B cells also decreased after a high fat 
diet (regardless of cholesterol level), but only for the wild type mice [Fig. 13a].  This 
decrease in transitional B cell percentages could be indicative of this subset’s migration 
into B cell follicles after an immune response.  The percentage of isotype switched B 
cells increased in wild type mice after a high fat/high cholesterol diet [Fig. 14a], but this 
same diet in L1 KO mice caused a decrease in this B cell subset [14b].  This data 
suggests that the cholesterol transporter L1 may be essential for the generation of isotype 
switched B cells during the immune response. 
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INTERPRETATIONS/SUMMARY: 
 In conclusion, the work conducted in the CD23 study and the data generated 
therein suggest that B cells that have undergone isotype switching (which are most likely 
memory B cells) have down-regulated expression of CD23 when compared to naïve B 
cells [Fig. 5c].  Since over-expression of the CD23 molecule has been directly associated 
with inhibition of the humoral immune response (i.e. antibody production), one could 
hypothesize that the low expression of this molecule on the isotype switched B cell subset 
(memory B cells) may be necessary in order to lower the activation threshold of these 
cells.  The study involving human B cells also showed that CD23 co-clustered with the 
BCR after in vitro stimulation, which implies a possible role in BCR-mediated B cell 
activation [Fig. 9].  It was also found that, in mice over-expressing CD23, there were 
slightly more isotype switched B cells in the spleen when compared to wild type mice 
[Fig. 8].  These observations might at first seem to contradict each other, until one 
considers that over-expression of CD23 could somehow drive isotype switching while 
also suppressing the activation of B cells. 
Analysis of B cell development in mice fed with different diets suggests that the 
high fat diet somehow stimulates an increase in FO B cells in both the wild type and L1 
KO mice regardless of the level of cholesterol [Figs. 10a, 10b].  This data appears to be 
consistent with recent studies suggesting that diets high in fat can stimulate immune 
responses [57-59].  The data also shows that the high fat diet stimulates an increase in 
MZ B cells when coupled with low cholesterol in wild type mice [Fig. 11a], but in the L1 
KO mice an increase was seen in those fed the high fat diet regardless of the cholesterol 
content [Fig. 11b].  This data also seems to be consistent with generation of some form of 
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low-level immune response, but interestingly, wild type mice fed a high fat/low 
cholesterol diet did not generate a change in splenic MZ B cells when compared to those 
fed the normal chow diet [Fig. 11a].  The amount of T1 B cells appears to decrease when 
wild type mice are fed the high fat/high cholesterol diet [Fig. 12a], but the percentage of 
this same B cell subset only decreases in L1 KO mice when fed the high fat/low 
cholesterol diet [Fig. 12b].  The percentage of T2 B cells also decreased after a high fat 
diet (regardless of cholesterol level), but only for the wild type mice [Fig. 13a].  This 
decrease in transitional B cell percentages could be indicative of this subset’s migration 
into B cell follicles after an immune response.  The percentage of isotype switched B 
cells increased in wild type mice after a high fat/high cholesterol diet [Fig. 14a], but this 
same diet in L1 KO mice caused a decrease in this B cell subset [14b].  This data 
suggests that the cholesterol transporter L1 may be essential for the generation of isotype 
switched B cells during the immune response. 
When directly analyzing the effect of knocking out the NPC1L1 gene on the 
percentages of these B cell subsets, there appeared to be no difference in the amount of 
FO B cells present in the spleens of the L1 KO mice when compared to wild type 
regardless of the diet [Fig. 10c].  This suggests that the cholesterol transporter L1 does 
not directly impact B cell migration into follicles during the immune response.  The L1 
KO mice did, however, show an increase in the percentage of MZ B cells (6.2%) over 
wild type mice (3.5%) when fed the high fat/low cholesterol diet [Fig. 11c].  It is difficult 
to propose an explanation for this phenomenon since previous data/studies have shown 
that disrupting the expression of the L1 cholesterol transporter has a negative effect on 
the development of obesity-related metabolic disorders [45, 60, 61], which should 
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logically include indirect suppression of the inflammatory immune response.  The L1 KO 
mice did, however, show a decrease in the percentage of the MZ B cell subset when 
compared to the levels observed in wild type mice after being fed either the normal chow 
(1.9% vs 4.3%) or the high fat/high cholesterol diet (5.5% vs 8.9%) [Fig. 11c].  The T1 B 
cell subset saw an increase in percentage in the L1 KO mice over the wild type mice 
when fed either the normal chow (31.3% vs 26.4%) or the high fat/high cholesterol diet 
(20.9% vs 15.8%) [Fig. 12c].  This data could be evidence that the cholesterol transporter 
L1 is at least partially associated with the development of B cells out of the T1 stage.  
The high fat/low cholesterol diet showed a decrease of the T1 B cell percentage in the L1 
KO mice (21.1%) when compared to wild type mice (25.0%) fed the same diet [Fig. 12c].  
Interestingly, the L1 KO mice also saw a decrease in the T2 B cell subset when compared 
to wild type after either the high fat/high cholesterol (6.2% vs 7.9%) or normal chow diet 
(6.5% vs 10.7%) was administered [Fig. 13c].  Again, this data seems to suggest that the 
L1 cholesterol transporter plays a role in the development of B cells out of the T1 stage.  
The isotype switched B cell subset had an increase in percentage in the L1 KO mice 
(3.6%) over wild type mice (2.8%) after being fed the high fat/low cholesterol diet [Fig. 
14c], but this same subset showed a decrease in percentage for the L1 KO mice (2.5%) 
when compared to wild type mice (3.6%) after being fed the high fat/high cholesterol diet 
[Fig. 14c].  These final findings are somewhat difficult to explain as well.  An increase in 
the percentage of isotype switched B cells goes hand-in-hand with an increase in B cell 
stimulation and activation.  We also know that high cholesterol absorption can lead to 
activation of the inflammatory immune response.  If knocking out the NPC1L1 gene 
effectively blocks cholesterol absorption, then how might it be possible for L1 KO mice 
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fed a high fat/low cholesterol diet to have higher relative percentages of isotype switched 
B cells than wild type mice?  We currently know that the L1 transporter protein plays a 
crucial role in cholesterol absorption through the intestine, but perhaps this 
transmembrane protein also plays at least a small role in the reverse cholesterol transport 
system (RCT).  If this were the case (though admittedly, highly unlikely), it could be used 
to speculate that knocking out or interrupting the function of the NPC1L1 gene could 
conceivably lead to a slight buildup of cholesterol—enough at least to stimulate isotype 
switching in B cells.  A rather large problem with this theory is that other transporter 
proteins are still expressed in the L1 KO mice—namely a key player in the RCT system 
known as the ATP binding cassette (ABC) transporter.  Existing actually as a heterodimer 
comprised of both ABCG5 and ABCG8 proteins [62, 63], one of the more well 
established roles of this ABC transporter complex in the intestines is the active secretion 
of cholesterol out into the intestinal lumen [62, 64].  Once in the intestinal lumen, the 
cholesterol can then be excreted from the body.  In what way knocking out expression of 
the L1 transporter could affect the normal function of the ABC transporter complex or 
any of the RCT-associated proteins in this situation would need to be thoroughly 
explored before any preliminary conclusions could be drawn. 
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FUTURE DIRECTIONS 
Future Project #1: Identify the steps in memory B cell responses where CD23 plays a 
role. 
Purpose/Rationale:  The goal of this project is to investigate whether and where the CD23 
molecule plays its role in the development of memory B cells and the humoral memory 
response.  CD23 has been suggested to play a role in B cell activation, but the specifics 
regarding this role have not been elucidated [36].  Griffith et al. [39] found that cross-
linking surface CD23 by antibodies can enhance B cell activation and even override 
BCR-mediated signaling.  The findings that the over-expression and deficiency of CD23 
suppress and enhance both IgE and IgG antibody responses suggest that CD23 acts as a 
down-regulator of B cell-mediated immune responses [3, 34, 37, 55, 56, 65].  It remains 
unknown whether CD23 has a role in the development and activation of memory B cells.  
My preliminary data show a decrease in CD23 expression in memory B cells, implicating 
a possible down-regulation of a negative regulator in memory B cells.  In this future 
experiment, one would test the hypothesis that CD23 negatively regulates the generation 
of memory B cells and/or the activation and differentiation of memory B cells into 
plasma cells.  In order to address this hypothesis, one can use the CD23 knockout and 
transgenic mouse models.  First, it will be necessary to compare the relative percentages 
of different B cell subsets, particularly memory B cells in the spleens of wild type and 
CD23 knockout and transgenic mice, after immunization to identify which step of 
memory B cell development is regulated by CD23.  Secondly, one will need to examine 
the effect of CD23 expression on the frequencies of memory B cells and humoral 
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memory responses.  A third step would involve analyzing whether the expression level of 
CD23 has any impact on the differentiation of memory B cells into high-affinity plasma 
cells in vivo and in vitro.  Lastly, it would be interesting to investigate whether the effect 
of CD23 on memory B cells is originated from the B cells themselves and not other cell 
types.  This could be accomplished by adoptively transferring wild type, CD23 deficient 
or over-expressing B cells into B cell deficient mice and testing the generation of 
memory B cells and the differentiation of these B cells into antibody-secreting plasma 
cells.  These experiments will determine whether CD23 plays a role in regulating the 
generation of memory B cells and the activation and differentiation of memory B cells 
into high affinity antibody-secreting cells. 
Expected Results, Potential Pitfalls and Alternative Approaches:  I would expect to see a 
decrease in the percentage of memory B cells in CD23 transgenic mice when compared 
with that in CD23 knockout and wild type mice.  This could be associated with a lower 
frequency of high affinity antibody producing cells and low antibody titer in CD23 
transgenic mice.  CD23 may affect either the generation or activation of memory B cells 
or both.  Because CD23 is expressed in other immune cells in addition to B cells, the 
defects found in CD23 knockout and transgenic mice may not solely originate from B 
cells.  Therefore, adoptive transfer of B cells may lead to a partial defect.  In addition to 
adoptively transferring B cells into B cell deficient mice, and alternative approach could 
be to transfer wild type T cells with mutated B cells into irradiated wild type mice. 
Future Project #2: Determine how CD23 affects memory B cell activation. 
Purpose/Rationale:  This project investigates whether the expression, ligation, or 
colligation of the CD23 molecule can regulate BCR-mediated signaling in naïve and 
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memory B cells.  The colligation of BCR with CD23 has been shown to down-regulate 
BCR activation and cause an apoptotic response in naïve B cells [36].  In contrast, cross-
linking of CD23 with anti-CD23 antibodies has been found to increase naïve B cell 
activation [39].  How CD23 regulates BCR-mediated signal transduction and B cell 
activation remains to be explored.  BCR clustering is known to be a key step in the 
initiation of naïve B cell activation, and the recruitment of signaling molecules to BCR 
clusters leads to the formation of signalosomes [21, 28].  While activation mechanisms of 
memory B cells have not been well studied, it is reasonable to assume that memory B 
cells also share this characteristic.  The hypothesis is that CD23 can regulate signal 
transduction in B cells by influencing the kinetics and magnitude of surface BCR 
aggregation and by modifying signaling molecules recruited to BCR clusters.  My 
preliminary experiments show that the surface CD23 molecules co-cluster with surface 
BCRs in response to BCR cross-linking supporting the hypothesis.  To address the 
question of how CD23 regulates BCR-mediated signaling, one could use CD23 knockout 
and transgenic mouse models as well as human primary B cells.  The investigator would 
need to determine the effect of CD23 expression, CD23 ligation, and CD23-BCR 
colligation on the activation of proximal signaling molecules, on the kinetics and 
magnitude of surface BCR clustering, and on the recruitment of signaling molecules to 
BCR clusters.  These experiments would determine whether CD23 can regulate BCR 
signaling by modulating the formation of BCR signalosomes. 
Expected Results, Potential Pitfalls and Alternative Approaches:  I expect that CD23 
cross-linking and CD23-BCR colligation will have an impact on signaling in B cells.  
Colligation of CD23 with BCR may increase the activation of molecules responsible for 
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the down-regulation of BCR signaling.  If this is proven to be true, I also expect that 
colligation of CD23 to BCR will have a negative effect on BCR clustering as BCR 
clustering has been implicated as an important component of B cell signaling.  If no 
change in the activation of proposed signaling proteins is observed, the investigator could 
expand the spectrum of signaling molecules.  If one is unable to image CD23 and the 
BCR clusters using TIRF microscopy, they could instead try to colligate the BCR and 
CD23 with soluble antigen in vitro, stain the cells, fix the cells at various time points and 
then image them using confocal microscopy.  Utilizing this strategy would allow the 
investigator to visualize the forming of the BCR cap and how CD23 may co-localize with 
the cap.  One could also stain the cells for the activated signaling molecules by 
permeabilizing the cells and then treating with fluorescently tagged antibodies against the 
molecules of interest. 
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GLOSSARY 
 
Adjuvant – An immunological agent that increases the antigenic response. 
Amino Acid – An organic compound containing an amino group (NH2), a carboxylic 
acid group (COOH), and any of various side groups, especially any of the 20 compounds 
that have the basic formula NH2CHRCOOH, and that link together by peptide bonds to 
form proteins or that function as chemical messengers and as intermediates in 
metabolism. 
Anergic – Diminution or lack of immunity to an antigen. 
Antibody – Any of various proteins produced by B cells in response to the presence of an 
antigen. By becoming attached to antigens on infectious organisms antibodies can render 
them harmless or cause them to be destroyed. 
Antigen – Any substance that stimulates an immune response in the body (especially the 
production of antibodies). 
Atrophy – The partial or complete wasting away of a part of the body. 
Autoanitbody – An antibody that reacts with the cells, tissues, or native proteins of the 
individual in which it is produced. 
Autoimmunity – Of or relating to an immune response by the body against one of its 
own cells or tissues. 
B Cell – Any of the lymphocytes that mature in the bone marrow and, when stimulated 
by a particular antigen, differentiate into plasma cells. Also called B lymphocyte. 
Basophil – A leukocyte with basophilic granules easily stained by basic stains. 
Calcinuerin – A phosphatase that activates the transcription factor NFAT via 
dephosphorylation. 
Cancer – A	  class	  of	  disease	  in	  which	  a	  group	  of	  cells	  display	  uncontrolled	  growth	  
through	  division	  beyond	  normal	  limits,	  invasion	  that	  intrudes	  upon	  and	  destroys	  
adjacent	  tissues,	  and	  sometimes	  metastasis,	  in	  which	  cancer	  cells	  spread	  to	  other	  
locations	  in	  the	  body	  via	  lymph	  or	  blood.	  These	  three	  malignant	  properties	  of	  
cancers	  differentiate	  them	  from	  benign	  tumors,	  which	  are	  self-­‐limited,	  and	  do	  not	  
invade	  or	  metastasize.	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Chemokine – Any of various cytokines produced in acute and chronic inflammation that 
mobilize and activate white blood cells. 
Chemotaxis – The characteristic movement or orientation of an organism or cell along a 
chemical concentration gradient either toward or away from the chemical stimulus. 
Cholesterol – An animal sterol that is normally synthesized by the liver; the most 
abundant steroid in animal tissues. 
Cognate Antigen – The specific antigen that will bind to the BCRs of a given mature B 
cell. 
Complement – The complement system consists of a number of small proteins found in 
the blood, generally synthesized by the liver, and normally circulating as inactive 
precursors (pro-proteins). When stimulated by one of several triggers, proteases in the 
system cleave specific proteins to release cytokines and initiate an amplifying cascade of 
further cleavages. The end-result of this activation cascade is massive amplification of 
the response and activation of the cell-killing membrane attack complex. Over 25 
proteins and protein fragments make up the complement system, including serum 
proteins, serosal proteins, and cell membrane receptors. They account for about 5% of the 
globulin fraction of blood serum. 
Confocal Microscopy – An optical imaging technique used to increase optical resolution 
and contrast of a micrograph by using point illumination and a spatial pinhole to 
eliminate out-of-focus light in specimens that are thicker than the focal plane. It enables 
the reconstruction of three-dimensional structures from the obtained images. 
Cytokine – Any of several regulatory proteins, such as the interleukins and lymphokines, 
that are released by cells of the immune system and act as intercellular mediators in the 
generation of an immune response. 
Cytotoxic – Of, relating to, or producing a toxic effect on cells. 
Dendritic Cell – An antigen-presenting leukocyte that is found in the skin, mucosa, and 
lymphoid tissues and that initiates a primary immune response by activating lymphocytes 
and secreting cytokines. 
Differentiation – The process by which a less specialized cell becomes a more 
specialized cell type. Example: A naïve B cell differentiates into a memory B cell. 
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DNA – A nucleic acid that carries the genetic information in the cell and is capable of 
self-replication and synthesis of RNA. 
ELISA – A diagnostic tool in medicine and plant pathology, as well as a quality-control 
check in various industries. This technique is used to detect (and quantify) the presence 
of an antigen in a sample. 
ELISpot – The Enzyme-linked immunosorbent spot assay.  Developed in 1983 by Cecil 
Czerkinsky and is considered a common method for monitoring immune responses in 
humans and animals. 
Eosinophil – A type of white blood cell found in vertebrate blood, containing 
cytoplasmic granules that are easily stained by eosin or other acid dyes. 
Flagellin – The principal substituent of bacterial flagellum, and is present in large 
amounts on nearly all flagellated bacteria. 
Flagellum – A	  tail-­‐like	  projection	  that	  protrudes	  from	  the	  cell	  body	  of	  certain	  
prokaryotic	  and	  eukaryotic	  cells,	  and	  functions	  in	  locomotion. 
Flow Cytometry – A laser based, biophysical technology employed in cell counting, 
sorting, biomarker detection and protein engineering, by suspending cells in a stream of 
fluid and passing them by an electronic detection apparatus. It allows simultaneous 
multiparametric analysis of the physical and/or chemical characteristics of up to 
thousands of particles per second. 
Fluorescence – The emission of electromagnetic radiation, especially of visible light, 
stimulated in a substance by the absorption of incident radiation and persisting only as 
long as the stimulating radiation is continued. 
Germinal Center – A site within lymph nodes and lymph nodules (peripheral lymph 
tissues) where mature B lymphocytes rapidly proliferate, differentiate, undergo somatic 
hypermutation, and class switch their antibodies during a normal immune response to an 
infection. 
Granulocyte – A category of white blood cells characterized by the presence of granules 
in their cytoplasm. They are also called polymorphonuclear leukocytes (PMN or PML) 
because of the varying shapes of the nucleus, which is usually lobed into three segments. 
Immunization -- The process of inducing immunity to an infectious organism or agent in 
an individual or animal through inoculation with the organism or agent. 
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Immunoglobulin -- Any of a group of large glycoproteins that are secreted by plasma 
cells and that function as antibodies in the immune response by binding with specific 
antigens. There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM. 
Immunology -- The branch of biological science concerned with the study of immunity. 
in vitro – Made to occur outside the living organism in an artificial environment, such as 
a culture medium. 
in vivo – In the living organism. 
Isotype – The genetic variations or differences in the constant region of the heavy chain 
of the Ig (immunoglobulins) classes and sub-classes. 
Isotype Switching – A biological mechanism that changes a B cell's production of 
antibody from one class to another, for example, from an isotype called IgM to an isotype 
called IgG. 
Kinase – Alternatively	  known	  as	  a	  phosphotransferase,	  it	  is	  a	  type	  of	  enzyme	  that	  
transfers	  phosphate	  groups	  from	  high-­‐energy	  donor	  molecules,	  such	  as	  ATP,	  to	  
specific	  substrates	  in	  a	  process	  referred	  to	  as	  phosphorylation. 
Knock Out – A genetic technique in which an organism is engineered to carry genes that 
have been made inoperative (have been "knocked out" of the organism). 
Leukocyte – Any of various blood cells that have a nucleus and cytoplasm, separate into 
a thin white layer when whole blood is centrifuged, and help protect the body from 
infection and disease. Includes neutrophils, eosinophils, basophils, lymphocytes, and 
monocytes. Also known as white blood cells (WBC). 
Lipid – Any of a group of organic compounds, including the fats, oils, waxes, sterols, 
and triglycerides, that are insoluble in water but soluble in nonpolar organic solvents, are 
oily to the touch, and together with carbohydrates and proteins constitute the principal 
structural material of living cells. 
Lymph – As the blood and the surrounding cells continually add and remove substances 
from the interstitial fluid, its composition continually changes and it changes into lymph 
fluid. It is then transported through lymph vessels to lymph nodes before emptying 
ultimately into the right or the left subclavian vein, where it mixes back with blood. 
Lymph Node – A small ball-shaped organ of the immune system, distributed widely 
throughout the body including the armpit and stomach/gut and linked by lymphatic 
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vessels. Lymph nodes are garrisons of B, T, and other immune cells. Lymph nodes are 
found all through the body, and act as filters or traps for foreign particles. They are 
important in the proper functioning of the immune system. 
Lymphocyte – A type of white blood cell in the vertebrate immune system, including 
NK cells, T cells, and B cells. 
Macrophage – A type of phagocytic white blood cell produced by the differentiation of 
monocytes in tissues. 
Mast Cell – A resident cell of several types of tissues containing many granules rich in 
histamine and heparin. Best known for its role in allergy and anaphylaxis. 
Memory B Cell – A B cell sub-type that are formed following primary infection.  
Responsible for rapid secondary immune responses. 
Memory T Cell – A specific type of infection-fighting T cell that can recognize foreign 
invaders such as bacteria or viruses, that were encountered during a prior infection or 
vaccination. At a second encounter with the invader, memory T cells can reproduce to 
mount a faster and stronger immune response than the first. 
Metabolism – A set of chemical reactions that happen in living organisms to maintain 
life. 
mRNA – Messenger RNA (mRNA) is a molecule of RNA encoding a chemical 
"blueprint" for a protein product. It is transcribed from a DNA template, and carries 
coding information to the sites of protein synthesis: the ribosomes. 
Naïve B Cell – A fully matured B cell that has not yet encountered its cognate antigen. 
Natural Killer Cell – A lymphocyte that is capable of binding to and killing virus-
infected cells and some tumor cells by releasing cytotoxins. It is found in the bone 
marrow and spleen. Its cytotoxic activity is not antibody-dependent but is augmented by 
interferon. 
Neutrophil – The most abundant type of granular white blood cell in mammals and 
forms an essential part of the innate immune system. 
Opsonization – A process whereby opsonins (ex: antibodies) make an invading 
microorganism more susceptible to phagocytosis. 
Phagocytosis – The cellular process of engulfing solid particles by the cell membrane to 
form an internal phagosome by phagocytes and protists. Phagocytosis is a specific form 
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of endocytosis involving the vesicular internalization of solid particles, such as bacteria, 
and is, therefore, distinct from other forms of endocytosis such as the vesicular 
internalization of various liquids. 
Phosphatase – An enzyme that removes a phosphate group from its substrate via 
hydrolysis. 
Plasma Cell – Also called plasma B cells, plasmocytes, and effector B cells, are white 
blood cells that produce large volumes of antibodies. 
Plasma Membrane – A biological membrane consisting primarily of phospholipids that 
separates the interior of all cells from the outside environment. 
Proliferation – Also known as ‘cell growth’. When used in the context of cell division, it 
refers to growth of cell populations, where one cell (the ‘mother cell’) grows and divides 
to produce two ‘daughter cells’. 
Protein – Organic compound made of amino acids arranged in a linear chain and folded 
into a globular or fibrous form. The amino acids in a polymer are joined together by the 
peptide bonds between the carboxyl and amino groups of adjacent amino acid residues. 
RNA – One of the three major macromolecules (along with DNA and proteins) that are 
essential for all known forms of life. 
Serum – The clear portion of any liquid separated from its more solid elements. 
Spleen – An organ in vertebrate animals that in humans is located on the left side of the 
abdomen near the stomach. It is mainly composed of lymph nodes and blood vessels. It 
filters the blood, stores erythrocytes, destroys old ones, and produces lymphocytes. 
Splenocyte – Any one of the different white blood cell types as long as it is situated in 
the spleen or purified from splenic tissue. 
Synergy – When any two or more agents work together to produce a result not obtainable 
by any of the agents independently. 
T Cell – Any of the lymphocytes that mature in the thymus and have the ability to 
recognize specific peptide antigens through the receptors on their cell surface. Also called 
T lymphocyte. 
Thymus -- a glandular organ of vertebrates, consisting in man of two lobes situated 
below the thyroid. In early life it produces lymphocytes and is thought to influence 
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certain immunological responses. It atrophies with age and is almost nonexistent in the 
adult. 
Titer – A measure of concentration. Titer testing employs serial dilution to obtain 
approximate quantitative information from an analytical procedure that inherently only 
evaluates as positive or negative. The titer corresponds to the highest dilution factor that 
still yields a positive reading. 
Transgene – An exogenous gene introduced into the genome of another organism 
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